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iINTRODUCTION
The British, it is said, are not revolutionary by nature. However, in the last century,
we created two organizations that have revolutionized the possibility and reality of
clinical research, with worldwide influence.
The first was the formation of the Medical Research Council (MRC). The Medical
Research Council was the successor of the Medical Research Committee, appointed
in 1913 to administer funds provided under the National Health Insurance Act of
1911 (see note 49). While there may be doubt whether or not these funds were
intended primarily for research into tuberculosis or for medical research more
generally, we cannot doubt the boldness of the step. A government set aside money for
medical research, rather than devoting the funds available for a medical problem solely
to prevention, diagnosis and treatment.
The second revolutionary step was the creation of the National Health Service. The
National Health Service Act of 1946 gave Ministers powers not only to conduct
research, but also to support the research work of others. The notion of a population-
wide, compre h e n s i ve healthcare system, free to the patient at the point of
consultation, and able to support the clinical infrastructure of research, was truly
revolutionary, and might have been impossible were it not for the appetite for social
change created by the Second World War.
The combination of government funding for medical re s e a rch, and a health service in
which re s e a rch on patients could be carried out, was a recipe for success. In this Wi t n e s s
Seminar we learn – from those who we re there at the time – of the success of this
combined ve n t u re. The Seminar brought together a re m a rkable group of individuals.
Some had undertaken clinical re s e a rch in the decades before the chosen starting point of
1950. We learn of the difficulties, whether created by institutions or by individuals, of
clinical re s e a rch in pre-war days. The situation was quite different in the 1950s. We hear
f rom many witnesses of the positive atmosphere, of the re s e a rch funds available for good
ideas from the MRC and other sources, of the symbiosis between the Health Se rvice and
u n i versities and of the freedom under which people could work. In Sheila Howarth’s
words (see page 10), research workers could be ‘rather a happy crew’.
This freedom was hard won, and the outcome of the battle to win it was, at times,
close.  We are reminded that provision for teaching and research in the National
Health Service Act was only secured following the intervention of members of the
1942 Club (see note 24). As well as the debate about whether the Medical Research
Committee was only intended to support research in tuberculosis, the extent to which
the Medical Re s e a rch Council would support re s e a rch in universities, or in
postgraduate institutions, or in its own research laboratories, was not clear. Again,
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evolution and happy chance led to a broadly-based portfolio of Research Council and
charity-funded research that led to the progress of the 1950s and 1960s. This was also
an era, as described by many who contributed to the Seminar, where those bodies that
did not actively support research also did not constrain it.
Howe ve r, the past, even through our rose-tinted spectacles, was not perfect. We learn
h ow some universities apparently resisted the opportunity of obtaining external funds
for re s e a rch. The geographical disposition of hospitals in London was not ideal, either
for their clinical service or (as a consequence) for re s e a rch. (This may explain the pre -
eminence in clinical re s e a rch of some of the great provincial schools in this post-war era.)
Most import a n t l y, Governments began to demand a different and more precise outcome
f rom their expenditure in re s e a rch. Politicians failed to learn the lessons of success: the
first quart e r - c e n t u ry of the National Health Se rvice had been re l a t i vely free of top-dow n
d i rection, and successful in the production of re s e a rch work of both fundamental and
applied importance. Contributors to the Seminar described, from their own experience
in the early 1970s, the process where by funds we re to be transferred from Re s e a rc h
Councils to their ‘c u s t o m e r’ departments (see note 149). It is inimical to the political
mind to allow freedom in the use of public money, against the possibility of post hoc
accountability: the urge is to control from the start. This Seminar showed the way in
which the reforms following the 1971 Rothschild Re p o rt and the 1972 White Pa p e r
we re introduced, made to work against all odds, and eventually disentangled. We would
hope that such disastrous shifts tow a rds more ‘d i re c t e d’ re s e a rch will not happen again
in the same way. 
Not all the failures in the era under re v i ew we re caused by political errors. Exc e l l e n t
ideas, such as the development of the Medical Re s e a rch Council’s Clinical Re s e a rc h
C e n t re, did not have the success that they deserved. The Seminar touches on this at
many points, but comes to no clear resolution as to why the Clinical Re s e a rch Centre
e ventually failed to obtain the backing (both financial and political) that it needed, and
was to close. This is a subject deserving of further study. One possibility is that the
f a i l u re lay in the hands of the Medical Re s e a rch Council, in not taking its ideas for a
clinical re s e a rch hospital through to completion earlier in the history of the Council.
The present Government, in the year 2000, repeatedly describes its programme for
u n i versities and for the Health Se rvice as one of ‘m o d e r n i z a t i o n’. What could be more
modern than a Health Se rvice, universities, Re s e a rch Councils, and others, all work i n g
t ow a rds a common aim of supporting excellent and applicable clinical re s e a rch? Du r i n g
the period cove red by this Se m i n a r, there we re many steps that we re thought to be tow a rd s
f u rther ‘m o d e r n i z a t i o n’. Some succeeded, but many failed.
We must learn from the re m a rkable group of individuals who gave so freely of their time
for this Seminar and who, in these pages, give us their own experience of an extraord i n a ry
era in clinical re s e a rch. 
David Gordon.
Dean of the Faculty of Medicine, Dentistry and Nursing,
University of Manchester
* The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to Twentieth
Century Medicine published by The Wellcome Trust.
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WITNESS SEMINARS: MEETINGS AND PUBLICATIONS*
In 1990 the Wellcome Trust created the History of Twentieth Century Medicine
Group to bring together clinicians, scientists, historians and others interested in
contemporary medical history. Amongst a number of other initiatives, the format of
Witness Seminars – used by the Institute of Contemporary British History to address
issues of recent political history – was adopted, to promote interaction between these
different groups, to emphasize the potentials of working jointly, and to encourage the
creation and deposit of archival sources for present and future use.
The Witness Seminar is a particularly specialized form of oral history where several
people associated with a particular set of circumstances or events are invited to meet
together to discuss, debate, and agree or disagree about their memories. To date, the
History of Twentieth Century Medicine Group has held 24 such meetings, most of
which have been published, as listed in the Table below.
Subjects for such meetings are usually proposed by, or through, members of the St e e r i n g
Committee of the Gro u p, and once an appropriate topic has been agreed, suitable
p a rticipants are identified and invited. These inevitably lead to further contacts, and more
suggestions of people to invite. As the organization of the meeting pro g resses, a flexible
outline plan for the meeting is devised, usually with assistance from the meeting’s
chairman, and some participants are invited to ‘set the ball ro l l i n g’ on particular themes,
by speaking for a short period of time to initiate and stimulate further discussion. 
Each meeting is fully recorded, the tapes are transcribed and the unedited transcript
is immediately sent to eve ry participant. Each is asked to check their ow n
contributions and to provide brief biographical details. The editors turn the transcript
into readable text, and part i c i p a n t s’ minor corrections and comments are
incorporated into that text, while biographical and bibliographical details are added
as footnotes, as are more substantial comments and additional material provided by
participants. The final scripts are then sent to every contributor, accompanied by
copyright assignment forms. All additional correspondence received during the
editorial process is deposited along with the re c o rds of this meeting in the
Contemporary Medical Archives Centre of the Wellcome Library.
As with all our meetings, we hope that even if the precise details of some of the
technical sections are not clear to the non-specialist, the sense and significance of the
e vents are understandable. Our aim is for the volumes that emerge from these meetings
to inform those with a general interest in the history of modern medicine and medical
science, to provide for historians new insights, fresh material for study, and pro m p t
f resh themes for re s e a rch, and to emphasize to the participants that events of the re c e n t
past, of their own working lives, are of proper and necessary concern to historians. 
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Lord Walton:1 It is a pleasure and privilege to have been invited to chair this meeting,
which is to examine who was responsible for clinical research in Britain between 1950
and 1980. Those dates have been chosen somewhat arbitrarily, but I think that it is
very relevant that there was so much development in clinical research, and in its
support from a variety of sources that began to emerge in the 1950s. Perhaps almost,
one might say, it reached a kind of zenith by 1980. I am grateful personally, because
I myself started in clinical research, I suppose, in the late 1940s, but I began work on
neuromuscular disease with a grant from the Department of Health, in 1951, and my
first personal research grant I brought back with me from the United States when I
had had a Nuffield Foundation Fellowship at the Massachusetts General [Hospital] in
1954, a grant from the Muscular Dystrophy Association of America. Subsequently, I
held many research grants, including 15 years as a programme grant holder from the
Medical Research Council (MRC), and I was personally a member of grant
committees and boards, and ultimately of Council between 1966 and 1978. My
personal involvement in medical research and in the governance of medical research
during that period was substantial. What I propose to do is to ask a number of people
to open on each topic for just a few minutes and then to open the meeting to a free
discussion. We are supposed to be looking at what is clinical research. What was the
effect of the National Health Service Act in 1948? How did the relationship between
the Medical Research Council, the charities, and foundations, and the NHS, and the
other professional bodies in medicine and medical science, how did those
relationships develop?2 And what was the impact of the National Health Service Act
upon medical research? I hope we shall look at expansion of the role of the MRC, the
1 Lord Walton of Detchant Kt TD FRCP FMedSci (b. 1922) was Professor of Neurology from 1968 to 1983 and
Dean of Medicine from 1971 to 1981 at the University of Newcastle upon Tyne. He was Warden of Green College,
Oxford, from 1983 to 1989. He served on the MRC from 1974 to 1978 and has been a member of the House of
Lords Select Committee on Science and Technology since 1991.
2 Professor Richard Himsworth wrote: ‘During the period under review the constitutional position of the MRC
within the governmental framework changed radically. In 1950 the MRC like other research councils came under
the Privy Council and the Lord President of the Council was a senior member of the Cabinet. This was a powerful
situation if there were problems with government departments. Furthermore the Secretary of the MRC negotiated
the budget directly with the Treasury. In late 1950s the Trend Report [Report of the Committee of Enquiry into the
Organization of Civil Science, under the chairmanship of Sir Burke Trend. Cmnd 2171. London: HMSO, October
1963, recommended the dissolution of the Department of Scientific and Industrial Research (DSIR) and the
creation of the Research Councils, implemented by the Science and Technology Act 1965] led to changes and a
transference of responsibility. As I recall Lord Hailsham was Lord President [1957–1959 and 1960–1964] but was
also designated Minister for Science [and Technology, 1959–1964]. Then a Ministry for Science was created
[1964, as part of the new Department of Education and Science] under which the Research Councils fell. All this
was long before Rothschild, but it made John Gray’s position very different from that of his predecessor at the
MRC. It has been, if not downhill, a process of distancing of the MRC from centre ever since, to its present
position in the framework for the government support of science through the Department of Trade and Industry
[funded through the Science Budget by the DTI via the Office of Science and Technology].’ Letter to Dr Tilli
Tansey, 23 June 1999.
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work of Sir Harold Himsworth3 and those who followed him, and, of course, the
influence of the Cohen Report, published in 1953, which had a seminal effect upon
the development of medical research.4
Perhaps at the outset I should remind you that in 1920 the Medical Research Council
was given a duty to promote medical research, and this included clinical research
which required access to patients and to clinical facilities. In 1926 an informal
agreement was reached between the MRC and the Health Departments,5 but local
arrangements depended upon agreements between boards of governors and hospital
management committees and other bodies, on the one hand, and researchers on the
other. The 1946 National Health Service Act made the Health Departments
responsible for all clinical facilities in a unified service after 1948 and gave the
Minister of Health powers to do research and to help others to do so; in 1947 similar
powers were given to the Secretary of State for Scotland. But in 1951, to avoid
confusion and conflicting interests, a joint subcommittee was set up between the
MRC and the Standing Medical Advisory Committee of the Ministry, and this also
had Scottish representation to make it acceptable to both Health Departments. Lord
Cohen of Birkenhead was the Chairman and the terms of reference were to devise a
scheme to use existing resources in a way that would be acceptable to all parties, and
to use those resources in the most effective way.
But, as I have already mentioned, it was the Cohen Report of 1953 which really set
the ball rolling as it took on board clinical research in the widest sense, including
epidemiology, social medicine, psychiatry and many other disciplines, as well as
general practice. It recommended that there should be central organization for
promoting research at a national level; careers in research that should be equated with
those in the NHS with free interchange between the two; and that a decentralized
research scheme should be established to encourage the spirit of research in the
periphery. Out of that report then arose the locally operated clinical research scheme,
which took some time to get under way. And the report stated (interestingly, plus ça
change) that nothing is more destructive to the morale of a research service than
discontent. Further recommendations were that a Clinical Research Board (CRB)
3 Sir Harold Himsworth KCB FRCP FRS (1905–1993), a distinguished clinical scientist, was Secretary of the
MRC from 1949 to 1968. As MRC Secretary he was not a member of Council until 1957 and there were other
changes arising from the Trend Report. He was appointed Professor of Medicine and Director of the Medical Unit
at University College Hospital (UCH), London, in 1939. His major project, the Clinical Research Centre, has
been described as a dream inspired by Sir Thomas Lewis. See Gray J, Booth C. (1994) Sir Harold Himsworth.
Munk’s Roll 9: 238–241.
4 Medical Research Council, Ministry of Health, Department of Health for Scotland, Central Health Services
Council, Advisory Committee on Medical Research in Scotland. (1953) Clinical Research in Relation to the
National Health Service. London: HMSO. Sir Henry Cohen (Lord Cohen of Birkenhead from 1956), of the
Standing Medical Advisory Committee of Central Health Services Council, was elected Chairman. See
Anonymous. (1953) Clinical research in the National Health Service. British Medical Journal ii: 140–141. This
editorial describes the report as a White Paper.
5 The Health Departments refer to the Ministry of Health, later the Department for Health and Social Security,
which covers England and Wales, and the Department of Health for Scotland.
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should be established, which would be under the MRC as the central supervisory body
for research programmes and research staff. Half the members would be MRC-
nominated, the other half would be chosen from Health Department nominees.
Research staff should, it was agreed, have the same status, with honorary clinical
contracts, salary, superannuation and eligibility for distinction awards, as the NHS
staff at that time. These were the main features of the Cohen Report; it was eventually
accepted in 1957, after four years, by the MRC and the Health Departments, both in
England and Wales, and in Scotland and Northern Ireland. That was really one of the
most important developments. What I now propose to do is to ask one or two people
who have agreed to do so to make preliminary comments about what they saw as
being major developments and problems which arose within that 1950–1970 period,
and then to continue with open discussion from the floor. So may I turn to Sir
Douglas Black and ask you, Douglas, if you would be good enough to comment upon
your perception of what you saw as the major benefits and problems of that period.
Sir Douglas Black:6 Thank you, Chairman. I can never resist the lure of an
unanswerable question, so let me put the one implied in our title, ‘What is clinical
research?’ If it simply means learning something from patients, that goes back to the
beginnings of medicine, if not before. But clinical research in a more formal sense was
given a tremendous boost early in this century, when it was realized, from the
examples of diabetes and pernicious anaemia, that physiological knowledge could be
applied to the cure, or perhaps more accurately palliation, of common diseases. That
gave people hope and interest in seeing what they could learn and apply in clinical
medicine. Much clinical research was done before it became a full-time career,
something which depended on the development of appropriate training. The year
1936 saw not only the start of the Wellcome Trust,7 but also the start of MRC
studentships and fellowships, which have enabled many – including myself – to make
a start in clinical research. Another milestone was the establishment by the MRC of
the Clinical Research Board in 1953, soon after Sir Harold Himsworth became
Secretary. Himsworth was not only an established clinician, but a man of wide
perspectives, ranging from molecular biology to psychogeriatrics. 
6 Professor Sir Douglas Black Kt FRCP FRCPath FRCPsych FRCGP (b. 1913) qualified at St Andrews University
in 1936 and held clinical and research posts in Dundee, Oxford and Cambridge before entering the Royal Army
Medical Corps from 1942 to 1946. He was appointed to the Department of Medicine at Manchester University
in 1946, becoming Professor of Medicine from 1959 to 1977, later Emeritus. He was Chief Scientist at the
Department of Health and Social Security from 1973 to 1977, a member of the MRC from 1966 to 1970 and
1971 to 1977; Chairman of the MRC Clinical Research Board from 1971 to 1973, Chairman of the Research
Working Group on Inequalities in Health from 1977 to 1980 and President of the Royal College of Physicians
from 1977 to 1983. He was an MRC Research Fellow from 1938 to 1940 and a Beit Memorial Research Fellow
from 1940 to 1942. See Inequalities in Health: Report of a research working group. London: DHSS, 1980. The report
became more widely available when published by Penguin in 1982 with an introduction by Peter Townsend and
Nick Davidson.
7 Sir Henry Wellcome (1853–1936) created the Wellcome Trust in his will dated 29 February 1932. It endowed
two research charities, one to support the history of medicine and the other to support research in medical sciences.
For details of the original will and subsequent developments, see Hall A R, Bembridge B A. (1986) Physic and
Philanthropy: A history of the Wellcome Trust, 1936–1986. Cambridge: Cambridge University Press.
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8 From 1 September 1974 three new re s e a rch boards we re introduced into the MRC ’s administrative stru c t u re :
Ne u robiology (later Ne u rosciences) and Mental Health Board; Cell Biology and Di s o rders Board, and Ph y s i o l o g i c a l
Systems and Di s o rders Board, each with one or two grants committees. In addition we re the En v i ro n m e n t a l
Medicine (Re s e a rch Policy) Committee and the Tropical Medicine Re s e a rch Board. House of Commons. (1974)
Medical Re s e a rch Council Annual Re p o rt, April 1973 – Ma rch 1974. HoC224. London: HMSO, 156.
9 Descriptions of ‘Clinical Research’ on page 7 were compiled by Dr Tilli Tansey and circulated at the Witness
Seminar, 9 June 1998. 
Now I would like to end with another question. I was the last Chairman of the
Clinical Research Board and was a party to the replacement of ‘horizontal’ boards
[Biological Research Board (BRB) and Clinical Research Board (CRB)] by three
‘vertical’ boards, designed to bring together people from different disciplines, but
working in the same field.8 This was a good initiative, in the sense that it allowed  the
meeting of different disciplines to foster the development of interdisciplinary research.
However, it also ended the earmarking of funds specifically for clinical research. The
question I raise is, ‘What impact the end of ‘ring-fencing’ may have had on clinical
research?’
Walton: Thank you very much, Douglas, for that preliminary introduction. May I
just add you will have before you a list of the definitions which have been suggested
by many people for clinical research, which you may find of some interest. [See box
on ‘Clinical Research’]9
I can’t forbear mentioning at this point, the little message that we’ve had from one of
those who sent his apologies, Roy Calne, who said that he was desperately sorry that
he couldn’t be with us. He said that when Sir Harold Himsworth went to visit him at
the Westminster at the beginning of his research career, he said to Roy, ‘Well, this
work looks quite interesting, we’ll give you a few thousand pounds to help you.’ No
forms to fill in, no animal rights people; research was much easier in those days, even
though money was tight. How things have changed. 
Next, I wish to ask Sir Raymond Hoffenberg. If you don’t mind, I think we can make
this very informal. Bill, when you came to this country in 1968, you must then have
been looking upon the clinical research scene in the UK as a kind of interested, but
in some respects an outside, observer.
Clinical Research in Britain 1950–1980
7
Clinical Research
‘I feel sure that Clinical Science has as good a claim to the name and rights and self-subsistence of a science
as any other department of biology; and that in it are the safest and best means of increasing the
knowledge of diseases and their treatment.’
J Paget (1870) quoted in T. Lewis (1935).See note 104.
‘This science in its widest outlook seeks first by observation and otherwise to discriminate between
diseases as these occur in man:it attempts to understand these diseases and their manifestations;it seeks
the cause of disease and studies its natural history;it attempts to cure or prevent disease; when it cannot
cure it endeavours to alleviate suffering. These are the objects of the science;the manner of its work may
be stated differently.’
T Lewis (1934) Clinical Science, Illustrated by Personal Experiences. London:Shaw.
‘Throughout the report we use the term “clinical research” to imply research into the mechanisms and
causation of disease, including its prevention and cure.Thus,in the sense in which we use the term,it covers
not simply work on patients in hospital but also field studies in epidemiology and social medicine and
observations in general practice.’
The Cohen Report (1953) See note 4.
‘Doctors in university clinical departments are applied scientists who bring to bear the traditional
disciplines of physics, chemistry, biology, anatomy, physiology and biochemistry into the clinical research
arena.This results in the conventional situation of biological mechanisms in health and disease being studied
in traditional scientific laboratories.’
A Guz (1976) The place of research.See note 145.
‘Clinical science – I have taken as my subject the study of the functional (physiological, biochemical, etc.)
disorders obser ved in sick people . Clinical science often also requires the study of structural, genetic and
other matters and its pursuit may well require studies of normal people and of animals.’
E J M Campbell (1976) Clinical science. In Research and Medial Practice:Their interaction. Ciba Foundation Symposium 44 
(new series),Amsterdam:Elsevier, 41–52,quote on page 41.
‘Clinical science today includes a wide range of subjects ranging from epidemiology to studies of individual
patients in depth and the laboratory analysis of specimens or tissues. It also involves the study of
experimental models of physiology and disease in animals where necessary.’
C C Booth (1987) Clinical research today. Transactions of the Medical Society of London102 : 24–41,quote on page 25.
‘Patient-oriented research (POR) is an integrative discipline. It copes with the complexity that is
characteristic of whole organisms in order to understand the components of that complexity. Basic POR
is the study of human beings (either patients or healthy volunteers) for the purpose of characterizing
disease processes more precisely, and for gaining new insights into human responses to disturbances in
chemical and behavioural makeup and to assaults by external factors.Thus, basic POR is involved in
management-of-disease questions, asking what is best, safest, and most useful among the drugs, vaccines,
and procedures under test.’
E H Ahrens (1992) The Crisis in Clinical Research:Overcoming institutional obstacles. New York:Oxford University Press.
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Sir Raymond Hoffenberg:10 Thank you, John. Although I migrated to Britain in
1968, I had spent some time in London in the early 1950s when I came to sit for the
Membership [the MRCP] examination and gain postgraduate experience. I was at the
[Royal] Postgraduate Medical School for a while, and it was an absolute eye-opener,
because very little research was being done in South Africa at that time and I was
impressed by the widespread research activity I encountered there. Facilities for
research were far from sophisticated. There was no automatic washing of glassware, it
all had to be done by hand; there were no calculators, one used a slide-rule; in my own
field of endocrinology, there was no hormone one could measure directly, most assays
were tedious, time-consuming and imprecise. Despite this, there was intense and
competitive research activity, which impressed me greatly and initiated my own
endeavours when I returned to South Africa.
I came back to England in 1968, thanks to the MRC, particularly to Sir Ha ro l d
Hi m s w o rth, and worked at the National Institute of Medical Re s e a rch [NIMR] at Mi l l
Hi l l ,1 1 w h e re my initial impression was that people seemed to spend ve ry little time at the
bench. They came in late, took long lunch breaks, went home early. It was only when I
found it necessary to come in late at night to bleed some animals that I re a l i zed they had
a different pattern of work, and at midnight and in the early hours the place was buzzing. 
By 1968 the research picture had changed greatly. It was no longer limited to
recognized research centres, but was evident in all the clinical institutions. Excellent
facilities were provided both at the NIMR and the Clinical Research Centre (CRC) to
which I moved when it opened in 1970. I found the same impetus to do research
when I went to Birmingham as Professor of Medicine in 1972. In those days of
relative affluence and governmental generosity, the MRC positively assisted one to get
an application right so as to improve the chances of getting a grant. They were
particularly helpful towards young people embarking on research for the first time.
Wa l t o n : Thank you ve ry much. I well recall that when John Gray wrote to me in 1966,
asking me to become a member of one of the grants committees, I was ve ry flattere d ;
on my ve ry first day at the MRC, I walked into those hallowed portals with a deep sense
of awe, feeling that I should walk rather quietly and that I was in the presence of the
g reat scientific minds of the country. I must say that I developed a great affection for
the Council over the next 12 years and felt that the mechanisms which it used for the
assessment of re s e a rch grant applications we re extraordinarily effective. The 0–6
grading system that was introduced during that period has, I think, stood the test of
10 Sir Raymond Hoffenberg KBE FRCP FRCPsych (b. 1923) emigrated to the UK in 1968, having been banned
by the South African government in 1967. He joined the MRC’s National Institute of Medical Research as Senior
Scientist in 1968, moving to the Clinical Research Centre, Northwick Park, Harrow, in 1970, until he was
appointed the William Withering Professor of Medicine at the University of Birmingham in 1972. He became
President of the Royal College of Physicians in 1983 to 1989, and of Wolfson College, Oxford, from 1985 until
1993, and was Professor of Medical Ethics at the University of Queensland from 1993 to 1995.
11 Mill Hill refers to the National Institute of Medical Research, which relocated there from Hampstead, London,
in 1949.
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time. How nice it was to think when one was on a grants committee then that grants
that we re scoring 2.9, 3.0, 3.1, we re getting through. How different that was from what
I have learned in more recent years. One person who knows a great deal about this era
and the re s e a rch scene is Sheila How a rth and I hope that you will be willing to share
some of your experiences with us. Sheila, would you like to tell us how you saw the
i n t e r relationship between the MRC at that time and the Health De p a rtments and the
operation of the NHS Act and anything else you consider re l e va n t ?
Dr Sheila How a rt h :1 2 Well, I was actually asked to comment initially on the first period,
f rom 1950 to 1963, which is when I went to the MRC ’s headquarters office. I re m e m b e r
my first encounter with Sir Ha rold Hi m s w o rth, who looked over his half-moons at me
and said ‘Ha, poacher turned gamekeeper’. So really this first period was my poacher
period and from that I re t i red in 1955 into domesticity for a while, and came in later to
the MRC. In 1950 I was working as a Senior Re s e a rch Fe l l ow in the Institute of
C a rd i o l o g y, which was one of the institutes of the British Postgraduate Me d i c a l
Federation of the Un i versity of London. This was part of an important organization set
up by a master of clinical re s e a rch organization, namely Sir Francis Fr a s e r,1 3 who was one
of the major people responsible for the establishment of the British Postgraduate Me d i c a l
School as it was then. In 1946 he formally resigned responsibility for the Chair and he
m oved to the British Postgraduate Medical Federation and from there he persuaded the
u n i versity to finance a whole series of institutes in the Un i versity of London. 
Let us not underestimate the role of the universities in this discussion. I haven’t heard
them mentioned very much so far. The Institutes were attached to the specialist
hospitals in London and by 1951 there were 13 of them and that in basic sciences was
added later;14 and although their primary function was perhaps postgraduate medical
education, nevertheless there was the hope, even the expectation I think, that they
would develop as centres of excellence in research, because the best people in the fields
were in fact on the staff of the specialist hospitals in their specialty and a number of
12 Dr Sheila Howarth FRCP (1920–2000) joined the staff of the headquarters office of the MRC in 1964. She
retired as Principal Medical Officer in 1980, having held responsibilities at office level for much of the MRC
clinical research programme, including the Clinical Research Centre. She had previously (1943–1945) been
engaged in research, mainly on the cardiovascular system, at the British Postgraduate Medical School, University
College London, and the Institute of Cardiology.
13 Sir Francis Fraser Kt FRCP (1885–1964) succeeded Sir Archibald Garrod to the Chair at St Bartholomew’s
Hospital in 1920 and was appointed the first Professor of Medicine of the British Postgraduate Medical School,
Hammersmith Hospital, London, in 1934. He became Director of the British Postgraduate Medical Federation
from 1946 to 1960. See Anonymous. (1968) Sir Francis Richard Fraser. Munk’s Roll 5: 141–142.
14 Morrow S E, Grahn M F. A History of the British Postgraduate Medical Federation (University of London). This
history (currently in preparation) was commissioned by BPMF Board of Governors at their final meeting prior to
disbandment, following which overall responsibility for the project was passed to Senate House, University of
London. See also Morrow S E. (1998) Research Strategy in UK Academic Medicine: Four case studies in the University
of London. Unpublished DPhil thesis, University of Sussex. The Institutes which provided these case studies were
the Institute of Dental Surgery (later the Eastman Dental Institute), the Institute of Child Health, the Institute of
Ophthalmology, and the Institute of Neurology, all of which have now become constituent parts of University
College London.
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appointments there were university appointments. There were professors, readers, and
people like myself as a senior research fellow, paid for by the university. They also gave
an opportunity for the development of ‘Cinderella’ subjects – clinical research, for
instance, in dermatology, and orthopaedics, dentistry, psychiatry, and even otology
and laryngology; and in this amalgam, the star in the crown was, of course, the British
Postgraduate Medical School,15 which later got its autonomy from the Federation.
And there was influence by the Federation in the periphery. Postgraduate medical
centres set up in the regions were linked to university medical schools and people were
encouraged to do research there – not very successfully. There were some good centres,
like Exeter for instance. But I don’t think the role of the universities should be omitted
in this discussion. 
If you look at it from the point of view of the worker, I think the research workers of
those days were really rather a happy crew. And it didn’t only apply to Hammersmith.
We weren’t looking over our shoulders all the time and worrying about our career
structure. We weren’t in posts which were inspected and constrained by programmes
which had to be approved and to which we had to conform. The emphasis in clinical
research was on people not on posts. 
The Health De p a rtments at that stage we re all for clinical re s e a rch. They hadn’t got
a round to manpower planning. Re s e a rch posts as defined in the Cohen Re p o rt, and
that famous document HM(57)36,1 6 we re supernumerary to the establishment of the
host institution, and clinical re s e a rch programmes we re, if necessary, supported by
NHS junior staff. A crew was provided, quite willingly, I don’t say on demand, but
on argument. This, of course, had a great effect on the re s e a rch work of the
Postgraduate Medical School, and initially on the CRC at No rthwick Pa rk, where we
fought desperately to have this agreement with the Health De p a rt m e n t s
implemented. I must say that the Royal Colleges didn’t do much about re s e a rch 
at that stage – saving the presence here of two of their illustrious presidents – but
they didn’t constrain it. T h e re we re no rigid training programmes, there was 
no general professional training, no JCHMT [Joint Committee on Higher Me d i c a l
Training] issuing programmes which had to be conformed to. And another 
factor which we we re spared in those days was the chronic ethical discussion 
and consideration. The ethics of clinical investigation at that stage was considered as
a personal matter between the investigator and the patient, and it wasn’t until
1962/63 when the MRC we re driven to produce their document on re s p o n s i b i l i t y
for re s e a rch in human subjects in their annual re p o rt that things really started to
m ove and the College [Royal College of Physicians] came into its ethical committees
15 Booth C C. (1985) Medical science and technology at the Royal Postgraduate Medical School: The first 50 years.
British Medical Journal 291: 1771–1779.
16 Ministry of Health. (1957) National Health Service: Clinical Research, HM(57)36. Ministry of Health
Memorandum to Regional Hospital Boards, Hospital Management Committees and Board of Governors,
summarizing arrangements for coordinating and financing clinical research in the Health Service and outlining the
powers and duties of the central research organization, the MRC’s Clinical Research Board, dated 30 April 1957.
A similar document [SHM(57)60] was circulated in Scotland.
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ro l e .1 7 In other words, the clinical research workers at the beginning of this period
under discussion still had a freedom which I think the basic scientists still enjoy. As
Bill Hoffenberg said, I’ve no doubt NIMR staff still enjoy that late breakfast to which
they think they have become entitled.
Wa l t o n : Thank you so much for the ve ry important points that have been raised.
Those we re, of course, some of the halcyon days where there we re a few
i n c o n t rove rtible principles that we re accepted, as you rightly said: one was the dual
s u p p o rt system1 8 in the universities, where by the universities we re re q u i red by the
Un i versity Grants Committee to provide the environment and infrastru c t u re and the
facilities in which re s e a rch could be carried out; while organizations, such as the MRC
and the charities, simply paid the direct costs and no overheads. Those we re import a n t
principles, as indeed was the principle of honorary clinical contracts for those employe d
on re s e a rch grants in clinical departments. That has all changed in recent ye a r s .
I wonder if I should mention two other things. No one has yet talked about the
growth of charitable funding for medical research. The Wellcome Trust, after all, was
founded in 193619 and it would be interesting to know when it and the charities began
to have a significant impact on the funding of research. Training fellowships in
methods of research in clinical medicine were introduced by the MRC as long ago as
1936. Clinical Research Fellowships came in 195020 and Senior Clinical Fellowships
were introduced by the Wellcome Trust in 1962. It will be interesting to have
comments from anyone in the audience upon the impact of these developments and
of course upon the role of the charities. So, Chris Booth, over to you.
Sir Christopher Booth:21 I wonder if I might make just three factual points. I entirely
17 Medical Re s e a rch Council. (1964) Responsibility in investigations on human subjects: Statement by Medical Re s e a rc h
Council. British Medical Jo u rn a l i i: 178–180. The statement from the MRC ’s Annual Re p o rt for 1962–63 (Cmnd 2382,
London: HMSO) was re p o rted in full and distinguished between pro c e d u res for the benefit of the individual patient
and those conducted to contribute to medical knowledge. Guidelines we re given on clinical trials, withdrawal of patients
f rom a collective controlled trial, freely given consent versus written consent, and rights of minors or mentally
handicapped, as well as a code of professional discipline beyond the minimum specified in law. The statement was
p receded by the Declaration of Helsinki, a code of ethics of the World Medical Association, accepted in June 1964.
18 The MRC’s Annual Report for 1969–70 describes the dual support system as one where ‘public funds are made
available in a non-selective manner through the University Grants Committee to provide a basic unit of support
for the research of all university teachers. At the same time a selective provision of public funds is made through
the Research Councils.’ (page 2)
19 See note 7. 
20 The MRC Clinical Research Fellowships were first awarded in 1951. Committee of Privy Council for Medical
Research. (1952) Report of the Medical Research Council for the Year 1950–51. Cmnd 8584. London: HMSO. See
the central topic of discussion, ‘The Training of Research Workers’, 4–7. The other two forms of support were the
postgraduate scholarships and travelling scholarships. 
21 Sir Christopher Booth Kt FRCP (b. 1924) trained as a gastroenterologist and was the first Convenor of the
Wellcome Trust’s History of Twentieth Century Medicine Group, from 1990 to 1996 and Harveian Librarian at
the Royal College of Physicians from 1989 to 1997. He was Professor of Medicine, Royal Postgraduate Medical
School, Hammersmith Hospital, London, from 1966 to 1977 and Director of the MRC’s Clinical Research
Centre, Northwick Park Hospital, Harrow, from 1978 to 1988.
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agree with your point about the Clinical Research Fellowships of 1936. As Sir Douglas
Black has pointed out, he was one of the first holders. Another whom we all remember
now was Sir John Dacie,22 who started his research career with one of those MRC
fellowships in 1936. The second point is that the first chairman of the Clinical
Research Board was in fact the Manchester neurosurgeon, Sir Geoffrey Jefferson,23
who was very highly regarded by Sir Harold Himsworth and who made a real impact
on developing clinical research through the Board. The third point is Sir Harold’s own
position vis-à-vis the Department of Health and I think here we have to go back
before the foundation of the National Health Service. When Nye Bevan put up his
Bill to Parliament, there were a number of defects in it, and Sir Harold and two of his
colleagues in the ‘42 Club’24 noted that in the Bill there was no allowance within the
new health service for teaching and research and they made a row about that and tried
to persuade Bevan to change it. Bevan, according to Himsworth, hit the roof and said
he’d had nothing but trouble with the doctors all the way through and he was damned
if he was going to have any amendments to his Bill at this stage. Fortunately
Pickering25 had a link with Sir Christopher Addison, by then Lord Addison in the
House of Lords,26 and through him they were able to get an interview with the
Chancellor, who was then Lord Sankey, and it was he who agreed that there would
have to be an amendment in the Lords to the National Health Service Bill, making
sure that the Minister had a responsibility not only for health care but also for the
supporting education and research. That meant that when Himsworth became
Secretary of the MRC in 1949 he was in a strong position, knowing that that had
happened, to say to the Department, ‘Look, you have a responsibility for research’;
22 Professor Sir John Dacie Kt FRCP FRS (b. 1912) was Professor of Haematology at the Royal Postgraduate
Medical School, Hammersmith Hospital, London, from 1957 to 1977, now Emeritus. 
23 Sir Geoffrey Jefferson CBE Kt FRCS FRS (1886–1961), was Professor of Neurosurgery at the University of
Manchester from 1939 until his retirement in 1951. A consultant neurosurgical adviser to the Ministries of Health
and of Pensions during the Second World War, he joined the MRC in 1951 and was Chairman of the Clinical
Research Board from 1957 until his death. See Walshe F M R. (1961) Geoffrey Jefferson. Biographical Memoirs of
Fellows of the Royal Society 7: 127–135. 
24 Booth C. (1993) Friends and influence: The history of the ‘42 Club’. Journal of the Royal College of Physicians of
London 27: 187–191.
25 Sir George Pickering Kt FRCP FRS (1904–1980) was an assistant for eight years in Sir Thomas Lewis’s
Department of Clinical Research at University College Hospital, London, moving to St Mary’s Hospital Medical
School, London, to head the Medical Unit in 1939. The MRC established a Group for Research on Body
Temperature Regulation (later the Body Temperature Research Unit) under his direction in 1954. He went to
Oxford as Regius Professor of Medicine in 1956 to a new department of Clinical Research until his retirement in
1969. He was a member of the University Grants Committee from 1944 to 1954, and of the MRC and Clinical
Research Board from 1954 to 1958. A collection of his papers, CMAC/PP/GWP, is held in the Contemporary
Medical Archives Centre of the Wellcome Library.
26 Lord Addison KG PC FRCS (1869–1951) was Lord President of the Council in 1951 and Chairman of the
MRC from 1948 to 1951. He chaired a special MRC committee on phthisis (pulmonary tuberculosis) in relation
to occupations in 1914 when Parliamentary Secretary to the Board of Education. Before standing for Parliament
in 1910, he had been Hunterian Professor in 1901, Professor of Anatomy at University College, Sheffield, and
Examiner in Anatomy at the Universities of Cambridge and London. A copy of his 1918 memorandum on ‘Future
organization of medical research’ is reproduced in MRC (1952), note 20, 4–7.
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and in my view I think Himsworth made it quite clear that that was the background
to his ability to get the Health Department on board at that time.
Walton: Thank you very much for that important historical comment.
Dr Peter W i l l i a m s :2 7 May I say a little bit about that earlier period of the Clinical
Re s e a rch Board? I became a Medical Officer on the He a d q u a rters staff of the MRC in
the mid-1950s. I was responsible for processing all grants considered by its two Board s ,
the Clinical Re s e a rch Board and the Appointments and Grants [A&G] Committee. In
this capacity I presented the applications to these committees and there f o re got to know
the individual members quite well. I was a member of the division of the MRC run by
Frank He r r a l d ,2 8 who was the Se c re t a ry of the Clinical Re s e a rch Board. In those days it
would be quite common to have a casual chat with Hi m s w o rth on the stairs, and
He r r a l d’s division had coffee together most mornings. I there f o re saw the Clinical
Re s e a rch Board in action in what must have been about its second ye a r. Ge o f f re y
Jefferson was in the chair. It was exactly like the A&G Committee, the other Board of
the Council. It dealt with what its members believed was clinical re s e a rch. I think its
principal job, in the first place, was to assess the various re s e a rch units around the
c o u n t ry that had been taken over by the Health Se rvice and to decide whether it
b e l i e ved they we re worthy of recognition according to the MRC ’s standards of re s e a rch. 
I would like now to touch on another aspect, since the matter of training has come
up. If you were medically qualified and wanted to do research, you had to get an
income from somewhere. The research fellowships available were paid very poorly.
There appeared to be an attitude that if you wished to do research you were indulging
a private whim and should be treated like an artist in a Paris garret.
Wa l t o n : Thank you ve ry much, Pe t e r, for that comment. It’s interesting if you look at
M RC expenditure on clinical re s e a rch. T h e re was an extraord i n a ry disparity in the funding.
27 Dr Peter Williams CBE FRCP (b. 1925) was a Medical Officer on the headquarters staff of the MRC from 1955
to 1960. He joined the Wellcome Trust in 1960 and was its Director from 1965 to 1991 and Director of the
Wellcome Institute for the History of Medicine from 1981 to 1983.
28 Dr Frank Herrald CBE FRCPE was a member of the MRC headquarters staff from 1938, becoming a Senior
Medical Officer in 1949 and Principal Medical Officer from 1955 to 1970.
Approved expenditure on clinical research in 1952/53
18 research units £374 500
Special grant-aided projects 5 800
Clinical research grants 33 000
Clinical research fellowships 7 500
Clinical research scholarships 2 200
Clinical travelling fellowships 8 500
Total £431 500
M RC, Mi n i s t ry of Health, De p a rtment of Health for Scotland, Central Health Se rvices Council,
Ad v i s o ry Committee on Medical Re s e a rch in Scotland (1953) Clinical Re s e a rch in Relation to the
National Health Se rv i c e. London: HMSO. The Cohen Re p o rt. Fi g u res from Appendix on page 23.
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Just to answer your question about the Clinical Research Board, and the people who
were on it at that time when it was founded in 1957 were Geoffrey Jefferson,
Chairman, Dugald Baird,29 Henry Cohen,30 Charles Dodds,31 Charles Illingworth,32
Denis Hill,33 George Pickering,34 Robert Platt,35 Herbert Seddon,36 Wilfrid Sheldon37
and Brian Windeyer.38 All of them were very notable figures at the time. David
Gordon, I think you wanted to come in?
Dr David Gordon:39 Just one comment or question, if I may, to people who may
know the answer to this. The list that John Walton has read out of the money available
shows that of the total of £431 500 in 1952, there was a huge amount – £374 500 –
in research units. If you go back and read the very early reports of the Medical
Research Committee, later the Medical Research Council, there was an atmosphere
29 Sir Dugald Baird Kt FRCOG (1899–1986), gynaecologist and early exponent of abortion, was Regius Professor
of Midwifery at the University of Aberdeen from 1937 until 1965. He directed the MRC’s Obstetric Medicine
Research Unit there from 1955 until his retirement. See Thomson A L. (1975) Half a Century of Medical Research,
vol. 2. The programme of the Medical Research Council (UK). London: MRC, 93–94.
30 Lord Cohen of Birkenhead CH Kt FRCP (1900–1977) was Professor of Medicine at the University of Liverpool
from 1934 to 1965 and chaired many committees including the Central Health Services Council from 1957 to
1963 and the Ministry of Health’s Standing Medical Advisory Committee from 1948 to 1963.
31 Sir Charles Dodds Bt FRS (1899–1973) was Courtauld Professor of Biochemistry and Director of the Courtauld
Institute of Biochemistry at the Middlesex Hospital Medical School from 1927 to 1965, later Emeritus. He was
President of the Royal College of Physicians from 1962 to 1966; a member of the National Research Development
Corporation from 1949 to 1968; and one of the first members of the Clinical Research Board. See Dickens F.
(1975) Edward Charles Dodds. Biographical Memoirs of Fellows of the Royal Society 21: 227–267.
32 Sir Charles Illingworth CBE Kt FRCS (1899–1991) was Regius Professor of Surgery at the University of
Glasgow from 1939 to 1964, later Emeritus. 
33 Sir Denis Hill Kt FRCP FRCPsych (1913–1982) was Professor of Psychiatry in the University of London at the
Institute of Psychiatry from 1966 to 1979, then Emeritus. He was a member of the MRC from 1956 to 1960. 
34 For biographical note, see note 25.
35 Sir Robert Platt (Lord Platt of Grindleford from 1967) Bt FRCP (1900–1978) was Professor of Medicine at the
University of Manchester from 1945 to 1965 and a member of the Royal Commission on Medical Education from
1965 to 1968. He was President of the Royal College of Physicians from 1957 to 1962. See his autobiography,
Private and Controversial (London: Cassell, 1972). 
36 Sir Herbert Seddon Kt CMG FRCS (1903–1977) was Honorary Consulting Surgeon to the Royal National
Orthopaedic Hospital, Stanmore, Middlesex, and Professor of Orthopaedics at the University of London from
1965 to 1967. He was a member of the MRC from 1956 to 1959, and of the Clinical Research Board, the Colonial
Advisory Medical Committee and the Tropical Medicine Research Board. 
37 Sir Wilfrid Sheldon CVO KCVO FRCP (1901–1983), was Physician-Paediatrician to the Queen from 1952 to
1971 and Consulting Paediatrician to King’s College Hospital and Consulting Physician to the Hospital for Sick
Children, Great Ormond Street. He was an Adviser in Child Health to the Ministry of Health. See Stroud C E.
(1984) Sir Wilfrid (Percy Henry) Sheldon. Munk’s Roll 7: 531–532.
38 Professor Sir Brian Windeyer Kt FRCP FRCS (1904–1994) was Professor of Radiology (Therapeutic) in the
University of London from 1942 to 1969. He served two terms as a member of the Council of the MRC and was
a member, later Chairman, of the Clinical Research Board from 1954 to 1962.
39 Dr David Gordon FRCP FMedSci (b. 1947), co-organizer of this Seminar, was seconded to The Wellcome Trust
from St Mary’s Hospital Medical School in 1983, joining the staff of the Trust in 1985 as Assistant Director and
later Programme Director, with particular responsibility for the support of clinical research. He became Professor
of Medicine and Dean of the Faculty of Medicine, Dentistry and Nursing at the University of Manchester in 1999.
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there that we were going to do medical research, and we were going to build an
institute to do it in, and the universities that Sheila Howarth mentioned were almost
put on one side. Indeed I believe there was pressure in the early days on Almroth
Wright,40 and such like people, to step outside of their university posts and become
full time in this institute [the National Institute for Medical Research (NIMR)]. What
caused the shift from a budget that was to be very much based in largish units into the
more diffuse budget for university-based research that we actually recognize in the
later days of the MRC? What actually made that move?
Walton: In your time, John Gray, there was a formula, was there not, that a certain
percentage of MRC expenditure should be spent on the units and that there should
be a certain percentage set aside for programme grants and for project grants. Do you
remember what that percentage was?
Sir John Gray:41 I don’t remember that there was a particular laid-down percentage.
What was certainly true was at the time I became Secretary and before that, we were
trying to increase the proportion of monies spent on grants as against our own staff.
But you have to remember one or two things about this, if you are looking at the
figures. The first is that when you employ a member of your own staff, you are
employing him completely, you are paying his salary, his pension, as well as all the
necessary things to allow him to work. If you gave a grant to somebody in the
university, when I was Secretary you didn’t have to pay the investigator’s salary, you
didn’t have to pay for his accommodation, you didn’t have to pay for his telephone or
his electricity. So that the amount of research the MRC got per pound of grant, was
probably something like three times as much as if you employed your own staff. So
those things were very different. 
The other thing that I specifically found when I took over from Harry [Himsworth],
was that while we were trying to increase the percentage of our budget going into
universities, we had the Clinical Research Centre coming on line. The formal opening
of the Clinical Research Centre was a year after I took over. Now, of course, this cost
money, and meant that as far as our accounts were concerned the proportion of the
MRC budget that was going on our own establishments actually started to go up
40 Sir Almroth Wright KBE Kt FRS (1861–1947), bacteriologist, was Professor of Pathology at St Mary’s Hospital,
London, from 1902 to 1946. He was mentioned as ‘the only man satisfying the requirements’ for the first Chief
Director of the National Institute for Medical Research in 1913, but the offer was never made. As Director of
Bacteriology, he had equal status with the three other directors of scientific departments of the NIMR, which was
run collectively. He remained at St Mary’s after the department moved to Hampstead in 1920, with a special grant
to support 25 research beds. See Thomson A L. (1973) Half a Century of Medical Research, vol. 1. Origins and
policy of the Medical Research Council (UK). London: MRC, 112, 115–116. Colebrook L. (1948–49) Obituary
Notices of Fellows of the Royal Society 6: 297–314, especially 304. See also Colebrook L. (1953) Almroth Wright:
Pioneer in immunology. British Medical Journal ii: 635–640.
41 Sir John Gray Kt FRS (b. 1918) was Professor of Physiology at University College London from 1959 to 1966
before joining the MRC as Second Secretary in 1966. He was Secretary from 1968 until 1977. On his retirement
he became a member of the external scientific staff of the MRC from 1977 to 1983 and at the Marine Biological
Association Laboratory at Plymouth from 1977 to 1993.
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again, rather than that to the universities. But in a sense that was a blip against the
policy trend.
Going back to something that Chris [Booth] said a moment ago, in 1939–1940 Harry
[Himsworth] was one of a small group put together by Sir Wilson Jameson, then a
professor at the School of Hygiene, before he became Chief Medical Officer at the
Ministry of Health.42 This group was put together to design a national health service,
so that when Wilson Jameson became Chief Medical Officer, and the Labour
Government came in, there were draft plans, if you like, ready in his mind, which
Harry had had a significant hand in.
P ro fessor Guy Scadd i n g :4 3 On the question of cooperation between universities and the
M RC, I have n’t yet heard mention of the Re s e a rch Group scheme which was
i n t roduced, I think, in the middle 1950s. At that time, I was Dean of the Institute of
Diseases of the Chest at the Brompton Hospital. We we re anxious to develop re s e a rc h
facilities in clinical immunology, for the Un i versity was unable to provide financial
s u p p o rt. Jack Pe p y s4 4 (whose son, Ma rk, has followed him into the field of immunology)
was providing clinical expertise, working part time as my clinical assistant, but had no
l a b o r a t o ry facilities. I went to talk to Ha r ry Hi m s w o rth, who arranged in 1960 that the
M RC would fund a Re s e a rch Group in clinical immunology at our institute. As I
understand it, the idea of these groups was that the MRC would support a group for five
years, and if at the end of the time it had proved to be successful, the unive r s i t y
u n d e rtook to continue it. The scheme certainly worked according to plan in this
instance, because it both initiated an active and pro d u c t i ve re s e a rch department and
e n s u red Jack Pe p y s’s distinguished care e r. I don’t know what happened to this scheme.
It was a good example of cooperation between university and the MRC .
Walton: Speaking as a former Dean, I think one of the reasons why that process which
was so admirable eventually fell by the wayside was because the universities no longer
found it possible to take over the actual appointments.
42 Sir Wilson Jameson GBE KCB FRCP FRCOG (1885–1962) was Chief Medical Officer to the Ministry of
Health during the planning and implementation of the National Health Service. He had been Dean and Professor
of Public Health at the London School of Hygiene and Tropical Medicine from 1929 to 1940, joining the Civil
Service as Medical Adviser to the Colonial Office in 1940, becoming Chief Medical Officer to the Ministry of
Health from November 1940 until 1950. He ser ved as a member of the MRC from 1940 to 1944.
43 Professor Guy Scadding FRCP (1907–1999) was Professor of Medicine in the University of London at the
Institute of Diseases of the Chest from 1962 to 1972, later Emeritus, and Honorary Consulting Physician at the
Brompton and Hammersmith Hospitals, London. He was Dean of the Brompton Hospital Medical School (later
the Institute of Diseases of the Chest) from 1946 to 1960, and a member of the Clinical Research Board from
1960 to 1965. He was involved with the MRC’s first controlled trial of streptomycin in 1947 and was author of
the 1968 report on the future of respiratory health services.
44 Professor Jack Pepys FRCP FRCPath (1914–1996) came to the UK from South Africa in 1947 to sit for the
MRCP. He worked in clinical immunology at the Brompton Hospital, London, setting up an allergy clinic at the
Institute of Diseases of the Chest, and in 1967 was appointed Professor and head of the first academic Department
of Clinical Immunology in the UK. The MRC funded his Clinical Immunology Research Group from 1960 to
1967 when financial responsibility was taken over by the Institute of Diseases of the Chest.
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Scadding: Exactly. I am fully aware of the great financial difficulty we had in taking it
over at the end of the five years, but we succeeded.
Walton: And at that time, too, the Nuffield Foundation used to establish chairs for
five years with the agreement that the university should take them over after a five-
year period. That was another scheme that fell by the wayside because of that
particular problem. Could I just ask you, arising out of what you said, John [Gray],
in which year was the Clinical Research Centre opened?
Gray: The formal opening must have been in 1970.
Wa l t o n : But the development, of course, was being planned for some time before that?
Gray: The development was almost certainly over by the time I first attended Council,
which was 1968.
Walton: Can I ask you, and any other member of the audience, whether the so-called
policy of the Wilson government relating to the white heat45 of technology had any
influence on the establishment of the Clinical Research Centre or whether it had any
influence at all on clinical research?
Gray: No!
Dr David Tyrrell:46 I’d like to mention a conversation that I still recall with Sir Harold
Himsworth, which bears on one or two of the points that have been made. This was
in about 1960 and I was barely settling into the Common Cold Unit,47 but there was
obviously a move afoot by Harold Himsworth to find suitable people to put into the
Clinical Research Centre and to start the planning work. He called me to his office to
talk about it. He explained the idea of having a Clinical Research Centre, and one of
the reasons he gave was that Sir Geoffrey Jefferson had been reviewing the sort of
clinical science that had been going on in the medical schools and found that it lacked
some of the things he thought the Medical Research Council should be engaged in.
He mentioned particularly work on common diseases and said they thought the best
way of doing this was to set up a research institute in close association with a district
general hospital. He asked whether I would be willing to go along and get involved in
setting it up? I said, ‘Yes, but of course’. But as we have been hearing, it took a very
long time before bricks and mortar were there and people were actually in posts. This
45 On 1 October 1963 Harold Wilson told the Labour Party Conference ‘we are redefining and we are restating
our socialism in terms of the scientific revolution...The Britain that is going to be forged in the white heat of this
revolution will be no place for restrictive practices or outdated methods on either side of industry.’ See Wilkie T.
(1991) British Science and Politics since 1945. Oxford: Blackwell, 39.
46 Dr David Tyrrell CBE FRCP FRCPath FRS (b. 1925), physician, virologist, previously Director of the MRC
Common Cold Unit, Salisbury, from 1982 to 1990 and Deputy Director of the Clinical Research Centre, Harrow.
He served as a Trustee of the Nuffield Foundation from 1977 to 1992 and on committees concerned with clinical
research ethics, genetic manipulation and use of dangerous pathogens.
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was something which I think was being developed as a result of the conceptions
forming in the Clinical Research Board which you have just discussed.48
Wa l t o n: Yes, thank yo u. We are not, of course, going to come to the period when the Clinical
Re s e a rch Centre was disbanded, but may I ask those who we re invo l ved in consultations at
that time to say whether they think that the concept was the right one; whether it was based
upon the idea of the US National Institutes of Health (NIH) with association between NIH
institutes and hospitals; whether the concept of putting it at a district general hospital
without a clear university association was the right decision? What do you feel?
Howarth: On a historical note can I just point out that the MRC, in 1919 in its
annual report, expanding on the decision not to develop a research hospital at Mount
Vernon, gave as its reasons not only the cost, but they said it was undesirable on every
ground to divorce research work from higher teaching.49
Booth: If I may, I might be permitted to quote from a personal conversation with Sir
Harold Himsworth on this particular point. When Sir Harold became Secretary of the
MRC in 1949, he was reasonably happy with the set up of units around and about,
and one has to remember that many of those units were in fact headed by honorary
directors, not full-time directors employed by the MRC, and many of them were
university professors, like George Pickering at St Mary’s, Dugald Baird in Aberdeen,
and in fact when Eric Bywaters’s chair came up at Hammersmith (and he is with us
today), there was a big argument. Sir John McMichael50 wanted to go on funding his
47 See Tansey E M, Reynolds L A. (eds) (1998) The MRC Common Cold Unit. In Tansey E M, Christie D C,
Reynolds L A. (eds) Wellcome Witnesses to Twentieth Century Medicine, vol. 2. London: Wellcome Trust, 209–268.
48 Dr Brandon Lush wrote: ‘Sir Ha rold Hi m s w o rth asked me to act as secre t a ry to a meeting he convened in his office
at Old Queen St reet in 1953 to discuss the setting up of a clinical re s e a rch centre. If I remember rightly, with Sir Ha ro l d
in the Chair, the others present we re Sir George Pickering, Sir Ro b e rt Platt, Sir Ed w a rd Wayne (who merits a mention
in the main text), Sir Charles Il l i n g w o rth, Sir Brian Wi n d e yer and Sir Dugald Ba i rd. My memory may be at fault, but
the MRC Head Office should still have a re c o rd of the meeting. I have a firm recollection of saying to Sir Graham Bu l l ,
when he told me that the Queen was to open the CRC that it was 17 years since Sir Ha rold had raised the matter.’ Letter
to Mrs Lois Reynolds 29 Ma rch 2000. Sir Ed w a rd Wayne Kt FRCP (1902–1990) was Regius Professor of Practice of
Medicine at the Un i versity of Gl a s g ow from 1954 to 1967 and Ho n o r a ry Physician to the Queen in Scotland from 1954
to 1967. He had been a member of the Scottish Se c re t a ry of St a t e’s Ad v i s o ry Committee on Medical Re s e a rch from 1958
to 1967, of the MRC from 1958 to 1972, and Chairman of the Clinical Re s e a rch Board from 1960 to 1964. 
49 Mount Vernon Hospital in Hampstead was purchased by the Medical Research Committee (later the Medical
Research Council) in 1913 and converted to house the National Institute for Medical Research, which after
wartime disruption, opened in 1920. For details of the decision not to include a research hospital, see Booth C.
(1989) Clinical research, in Austoker J, Bryder L. (eds) Historical Perspectives on the Role of the MRC: Essays in the
history of the Medical Research Council of the United Kingdom and its predecessor, the Medical Research Committee,
1913–1953. Oxford: Oxford University Press, 205–241, especially 208.
50 Professor Sir John Mc Michael Kt FRCP FRS (1904–1993) was Professor and Di rector of the De p a rtment of
Medicine at the Postgraduate Medical School at the Hammersmith Hospital, London, from 1946 to 1966, then
Di rector of the British Postgraduate Medical Federation from 1966 to 1971. His re s e a rch interests we re pre d o m i n a n t l y
in the field of cardiology and he was the first (with E P Sharpey-Schafer) in Britain to apply the technique of card i a c
catherization. He was a Beit Memorial Fe l l ow from 1932 to 1934, a member of the MRC from 1949 to 1953, and a
Trustee of the Wellcome Trust from 1960 to 1977 and was founder of the Senior Clinical Re s e a rch Fe l l owships in 1962.
See Do l l e ry C. (1995) Sir John Mc Michael. Bi o g raphical Memoirs of Fe l l ows of the Royal Society 4 1: 283–296.
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salary from university sources and, I believe, that is in fact what happened. Himsworth
told me that he couldn’t understand that, when he was personally prepared to pay the
salary himself as an MRC unit. But, turning to Himsworth’s position over the unit.
What he felt was that, after looking around, many of the units were too small and did
not have the effective basic science associated with them to be able to make an
effective dent in the research that they were doing and he quoted, for example: ‘That
some units were having to make do with a PhD postdoc as a biochemist, to do all the
biochemistry that was needed for their research’. He therefore asked Geoffrey Jefferson
to go round and look at the various units and consult widely and see whether there
was a need for something better.51 It was that survey that came up with the idea that
there should be a central organization where you could get the basic science and other
people working together.
Remember too that Harold Himsworth was deeply distressed when Mill Hill52 was set
up in the late 1940s, when Henry Dale moved out to that site. He took the view that
it should never have been developed as an isolated site, but should have been on a
hospital base, and he took that view throughout. When he was involved in developing
the Clinical Research Centre concept one must remember too that a basic tenet of that
proposal was that Mill Hill [NIMR] would move to the Northwick Park site. All the
time that I was at Northwick Park, we had a lease on land there for rebuilding Mill
Hill, so it was looked upon as a major development for the whole of the MRC’s
activity, not just a clinical research programme.
Gordon: A comment, that this seems to be a recurring event. When the Postgraduate
Medical School was proposed, it was initially suggested that this should be in
association with a teaching hospital fairly central in London, but there was nowhere
that would take it, and it went out of central London to the Hammersmith Hospital
in Du Cane Road. There seems to be a resistance, a conservatism, to placing a research
institute in proximity to an existing academic hospital.
Hoffenberg: There are several here who were founder members of the Clinical
Research Centre. Looking back, one wonders whether it was such a good idea to try
to create a community research hospital at Northwick Park. I say this because there
was concern locally, amongst the community at large as well as the general
practitioners, that it would become an experimental hospital. The MRC, and the
CRC Director, Graham Bull,53 had to make concessions to reassure them that this was
not the case and that proper care would be provided. As a result, specialization was
discouraged and this impaired the recruitment of trainees who felt it necessary to
51 See note 49, Booth (1989), especially note 114 on page 238.
52 The National Institute for Medical Research (NIMR) moved to Mill Hill from Hampstead in 1949.
53 Sir Graham Bull Kt FRCP (1918–1987) was Director of the Clinical Research Centre at Northwick Park
Hospital, Harrow, from 1966 until his retirement in 1978. He had been Professor of Medicine at the Queen’s
University, Belfast, from 1952 to 1966 and a member of the MRC from 1962 to 1966. 
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acquire specialist skills for their future careers. It also led to the dominance of the
NHS consultants, most of whom were part time; some of these were excellent and
entered into the spirit of the place by active research; others were hardly ever there, set
bad examples to junior staff and impeded progress in their specialties.
Walton: I was for a time chairman of a committee that John Gray established, called
the NIMR/CRC Committee and we soon learned that that was one of the problems
that was clearly arising. Another problem was the lack of a formal association with a
university which made it difficult for people to register PhD students as they would
have wished; and the recruitment of surgeons with an academic interest was difficult
to such an extent that at one time the Director of the Division of Surgery was Sir Peter
Medawar,54 because no academic surgeon could be found to run the surgical division.
John Gray, I think that is true isn’t it of that particular time?
Gray: I can’t remember.
Booth: I promised that I wouldn’t get involved in this discussion after 1970, so I think
I would rather not comment on a period in which I was not involved. 
Professor Peter Lachmann:55 I would just like to make a comment on this. The MRC
recruited Eugene Lance as Director of the surgical department at Northwick Park,
who was indeed an academic surgeon.56 But the local regional board would not
establish a second transplantation unit at Northwick [Park] since there was already
one at Hammersmith, and so Gene Lance went off to Hawaii. 
Professor Richard Himsworth:57 Speaking as one who was at the CRC, I would like
to pick up on David Tyrrell’s comment that it was to concentrate on common diseases,
because certainly talking with my father that was one of the things that he was very
54 Sir Peter Medawar FRS (1915–1987) was Jodrell Professor of Zoology and Comparative Anatomy at University
College London from 1951 to 1962. He shared the 1960 Nobel Prize in Physiology or Medicine with Macfarlane
Burnet for the discovery of immunological tolerance. Between 1962 and 1971 he was Director of the National
Institute for Medical Research at Mill Hill, London, remaining on the scientific staff until 1984. See Mitchison N
A. (1990) Peter Medawar. Biographical Memoirs of the Fellows of the Royal Society 35: 283–301.
55 Professor Peter Lachmann FRCP FRCPath FMedSci FRS (b. 1931) was Sheila Joan Smith Professor of
Immunology at the University of Cambridge from 1977 until 1999, now Emeritus, and Honorary Director of the
MRC Molecular Immunopathology Unit (formerly MRC Mechanisms in Tumour Immunity Unit) from 1980.
He has been President of the Academy of Medical Sciences since 1998, of the Royal College of Pathologists from
1990 to 1993 and has served as Biological Secretary and Vice-President of the Royal Society from 1993 to 1998.
56 Professor Eugene Lance was Professor of Surgery at Cornell University and Assistant Surgeon at the Hospital for
Special Surgery in New York on his appointment to the Clinical Research Centre in 1969–1970.
57 Professor Richard Himsworth FRCP (b. 1937) has been Professor of Health Research and Development at
Cambridge University and Director of Research and Development in the East Anglian Regional Health Authority
since 1993. He was a member of the MRC’s Scientific Staff at the Clinical Research Centre from 1971 to 1985,
Assistant Director from 1978 to 1982, Head of the Endocrinology Research Group from 1979 to 1985 and
Consultant Physician at Northwick Park Hospital from 1972 to 1985. He was Regius Professor of Medicine at the
University of Aberdeen and Hon Consultant Physician at the Aberdeen Royal Infirmary from 1985 to 1993.
Clinical Research in Britain 1950–1980
21
keen on. He said that you should bring good science together with common diseases
and he did not think that any of the existing teaching hospitals, including the
Hammersmith, which was looked at as a site for the CRC, could do that because they
already had established tertiary referral patterns that were distorting the kinds of
patients which came there. I think he was quite conscious of that. If I could also go
on to the point which was made about the difficulties with the universities and being
able to supervise PhDs, which I remember vividly: some of you will know that Peter
Medawar was told he could no longer supervise PhDs when he was at Mill Hill by the
University of London, because he didn’t have a university position, and so the CRC
had, I think, in Keith Kirkham, to work very much through the Council for National
Academic Awards (CNAA) for higher degrees.58
Professor Abe Guz:59 Two points. First of all I can confirm what Sir Raymond
[Hoffenberg] has said about the desire to have a lot of ‘ordinary’ doctors there for the
sake of the population, as I had a personal conversation with Graham Bull. I had a
superb person at the time who I was putting forward for a post and he actually said
to me, ‘He is far too good for what I am planning’. I remember that distinctly, because
quite frankly, I was shocked. 
I also want to say that we haven’t discussed much about the universities’ reaction to
the research funds that were available, in terms of accepting and being interested in
research. I seem to remember the time when there were an awful lot of medical
schools, certainly in London and some outside, that were really not interested (with
some exceptions) in having some of their money coming to them from elsewhere. In
my own medical school it’s widely known that my boss, Hugh de Wardener,60 actually
spent time trying to get the Dean of the day, a very powerful figure, who refused to
sign an application form for a grant that the National Institutes of Health (NIH),
Bethesda, Maryland, wanted to give him. This was said at the Academic Board – I
wasn’t on it, but I was told – because, it was said, that would remove the power from
where it should be. I am sure that my own medical school was an awful school at the
time from this point of view, but there were others, and I had heard this sort of thing
before! That was a rather grotesque example, but I wonder how common it was in the
ordinary medical schools, the undergraduate medical schools?
58 Dr Keith Kirkham OBE (b. 1929) was Administrative Director of the MRC’s Clinical Research Centre,
Northwick Park, Harrow, from 1988 to 1994. He was a member of the scientific staff of the MRC Clinical
Endocrinology Research Unit from 1960 to 1973 and Assistant Director (Administration) of the CRC from 1973
to 1988. The Council for National Academic Awards awarded degrees and higher degrees from 1964 until it was
abolished in 1989.
59 Professor Abe Guz FRCP (b. 1929) has been Professor of Medicine at (the then) Charing Cross and Westminster
Medical School from 1981 until his retirement in 1994. He qualified at Charing Cross, and was a Research Fellow
at Harvard Medical School and the Cardiovascular Research Institute, University of California, returning to
Charing Cross in 1961 as Lecturer, later Senior Lecturer and Reader.
60 Professor Hugh de Wardener CBE FRCP (b. 1915) held the Chair of Medicine at Charing Cross Hospital,
London, from 1960 to 1981, later Emeritus. 
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Walton: I can only speak for the North-East, my own native city and the University
of Newcastle upon Tyne, where they would grab any money that was coming from
anywhere. We didn’t ever have that problem in the 1950s to 1970s, it only emerged
as a difficulty in the 1980s.
Dr Brandon Lush:61 Can I just say something about common diseases? I joined the
MRC head office staff at the beginning of 1951 and Harry Himsworth had just asked
the late Sir Wilson Jameson if he would chair a new committee on social and
environmental health. I well remember Jameson sitting in a chair in my office, looking
over his half-moon glasses at me and saying: ‘Well, Lush, what ought we to do?’ and
we discussed a number of things, one of which was research in general practice.
Jameson felt very strongly that there was a vast amount of knowledge in general
practice which wasn’t being adequately gathered and researched upon, so we set up a
w o rking party under the Chairmanship of the late Sir James Sp e n c e ,6 2 w h o
unfortunately died within a year, and Sir Robert Platt,63 as he then was, succeeded
him. We got together a group of very good general practitioners and published quite
a lot of work, which is one of the factors which I think that helped in the setting up
of the College of General Practitioners, later the Royal College of Ge n e r a l
Practitioners,64 so Harry Himsworth’s influence in getting common diseases and
problems tackled, extended through Jameson to the wider field of general practice.
Professor Alan Glynn:65 Two points. One, sometime in the 1960s I was on a research
grant committee of the Northwest Thames Regional Board and we used to get a lot
of applications from junior staff at Northwick Park. We didn’t have much money and
we always used to say, ‘Why can’t you get some money from the MRC?’ And the
answer was that if you were in the NHS-half of the Clinical Research Centre, you
couldn’t. I have always felt, although I never knew the details, that there was some
confusion in the organization there, which was a pity. The other thing I would just
like to put on record was that I was a student at University College Hospital when
61 Dr Brandon Lush FRCP (b. 1920) was a member of the MRC staff from 1951 and Principal Medical Officer
at the MRC from 1961 to 1972. He was Secretary of the Tropical Medicine Research Board from its creation in
1960. He then became a Consultant Physician at the Frenchay and Manor Park Hospitals, Bristol, from 1973 to
1985. He was Chairman of the Mason Medical Research Foundation from 1972 to 1982 and President of the
Cossham Medical Society from 1992 to 1993.
62 Sir James Spence Kt FRCP (1892–1954) was the first holder of the Nuffield Chair of Child Health, the first of
its kind in England and Wales, at the University of Durham from 1942 until his early death. He was a member of
the University Grants Committee and of the MRC from 1944 to 1948 and from 1952. See Miller F J W. (1997)
Sir James Spence, Professor of Child Health. Journal of Medical Biography 5: 1–7.
63 For biographical details, see note 35.
64 See Reynolds L A, Tansey E M. (eds) (1998) Research in General Practice. In Tansey E M, Christie D A,
Reynolds L A. (eds) Wellcome Witnesses to Twentieth Century Medicine, vol. 2. London: Wellcome Trust, 75–132.
65 Professor Alan Glynn FRCP FRCPath (b. 1923) practised clinical medicine at St Mary’s Hospital, London, from
1956 to 1958. He took up bacteriology at St Mary’s, was appointed Professor in 1971 and Head of Department
of Bacteriology in 1974. In 1980 he became Director of the Central Public Health Laboratory at Colindale until
his retirement in 1988.
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Harry Himsworth went to the MRC. I had been on his firm and there was complete
dismay at UCH, among the students at any rate, at the thought of losing this
tremendous teacher.
Walton: Yes, thank you very much. Can I go back to the point that Abe Guz made.
Was this phenomenon of resistance on the part of the universities to accepting
research grants nationwide? Can anyone answer and was it the case in the 1950s to
1970s? I recognized it coming much, much later, but at that time I thought that
anyone was happy to accept such grants.
Howarth: I wanted to say that at this period there were some very rich hospitals. St
Thomas’ Hospital medical unit, for instance, ran its research programme entirely at
this stage on the interest from the endowment funds of the hospital, so they didn’t
need to apply elsewhere. I can remember the first chap who did apply for an outside
grant was looked on as a very strange sort of animal. I think the same situation
probably applied at Bart’s and Guy’s, but these again were the rich hospitals.
Walton: And another point was that there were certain clinical institutions at that
time which were very suspicious about the influence of the universities. I worked as a
visiting fellow in Carmichael’s neurological research unit at Queen Square for a year
from 1954 onwards, and it was an article of faith on the part of the consultant staff at
Queen Square that they had nothing whatever to do with the university. It was an
extraordinary attitude and Carmichael’s unit was looked upon very much as an odd
parasite in the middle of a clinical hospital.66
Professor Sir Stanley Peart:67 I think one has got to recognize the atmosphere in the
London teaching hospitals. If I look back to when I was appointed in 1956 to succeed
George Pickering as Professor of Medicine and before that, the hospital I was in, St
Mary’s, which really was so like so many of the other teaching hospitals, the staff were
actually undoubtedly enemies of clinical research. You had to really work very hard to
get the confidence of your clinical colleagues as consultants and that was the
atmosphere, I think, right through Britain. In fact, as I looked at what was going on,
I could only see one establishment in which the approach to clinical research was
given its due regard, and that happened to be the Hammersmith Hospital, because it
was the only place where they were encouraged to do research, certainly on the
medical side. On the surgical side perhaps less so, but you have got to remember also
that when I was appointed in 1956, in London only half the hospitals had a professor
66 The second clinical research unit, the Neurological Research Unit, was created by the MRC in 1933 under the
direction of Dr E A Carmichael CBE FRCP at the National Hospital for Nervous Diseases, Queen Square,
London, at the invitation of the hospital and continued until Carmichael’s retirement in 1961. See Thomson A L.
(1975) note 29, 19, 353.
67 Professor Sir Stanley Peart FRCP FMedSci FRS (b. 1922) was Professor of Medicine, University of London, at
St Mary’s Hospital Medical School, from 1957 to 1987, later Emeritus. He was a Trustee of the Wellcome Trust
from 1975, and Deputy Chairman from 1991 until 1994.
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of medicine at all. I call your attention to Guy’s in particular. You may remember that
one of your [to Lord Walton] noble colleagues was appointed as the Professor of
Experimental Medicine.68
Wa l t o n : It may be an apocryphal story, but medical students during the war in London
we re alleged to carry placards round their necks saying that, ‘If I am a casualty, don’t
send me to Ha m m e r s m i t h’. They all thought they would have cardiac catheters passed;
c e rtainly there was a ‘them and us’ attitude between the so-called practising clinicians
and the clinical scientists. How long did it take for that to be ove rcome? 
Peter W i l l i a m s : I think I have a bit of factual evidence. In the period between about
1958 and 1965 the Wellcome Trust spent the bulk of its income on providing buildings
for medical re s e a rch, rather than providing fellowships and expenses. I have looked at
the list of these grants and selected from it those that we re for clinical departments. T h e
list gives an indication of which we re the active places. Those receiving support we re
Belfast, Birmingham, Dundee, Edinburgh, Leeds, Ma n c h e s t e r, Newcastle, Oxford ,
Charing Cross, King’s College Hospital, St Ma ry’s, Westminster and the Institute of
Orthopaedics. Considering the number of medical schools in London, they re c e i ve d
surprisingly few. T h e re is, I think, no doubt at this stage that the provincial unive r s i t i e s
we re much more active than London in re s e a rch. One result was that the Clinical
f e l l owships we re held in these places. I have not included the Hammersmith in this list,
because it was in a different category. It re c e i ved a lot of support .
B o o t h : This is purely a factual account of unive r s i t y, supposedly unive r s i t y - b a s e d ,
schools resisting MRC money. R T Gr a n t ,6 9 of course, was always re g a rded by people
as the bar to Tom Lew i s’s FRS7 0 and he left Un i versity College to go to Gu y’s. He re t i re d
in 1957 and at that time Hi m s w o rth was ve ry concerned they should try and get a
successor to Grant to run the clinical re s e a rch unit on the Tom Lewis pattern at Gu y’s
Hospital, and if you read the correspondence about that there is little doubt that Gu y’s
was intensely suspicious of the MRC. One of the comments in the corre s p o n d e n c e
attributed to the Dean of Gu y’s: ‘ In t e rv i ewe d: the Se c re t a ry of the MRC ’ .7 1 That was
68 L o rd Bu t t e rfield of St e c h f o rd Bt Kt FRCP (1920–2000) was Professor of Experimental Medicine at Gu y’s Ho s p i t a l ,
London, from 1958 to 1963 and the Professor of Medicine at Gu y’s Hospital Medical School from 1963 to 1971.
69 Ronald Thomson Grant OBE FRCP FRS (1892–1989), a former member of Sir Thomas Lewis’s department at
University College Hospital, was Director of the MRC Clinical Research Unit at Guy’s Hospital, London, from
its creation in 1934 until his retirement in 1957 when the unit was discontinued. 
70 Sir Thomas Lewis Kt CBE FRCP FRS (1881–1945), Welsh cardiologist and clinical scientist, directed the first
of the MRC ’s re s e a rch units, the De p a rtment of Clinical Re s e a rch, established at Un i versity College Ho s p i t a l
Medical School, London, from 1919 until his re t i rement in 1945. He was awarded one of the first Beit Fe l l ow s h i p s
in 1910. See Lewis T. (1932) The relation of clinical medicine to physiology from the standpoint of re s e a rch. Br i t i s h
Medical Jo u rn a l i i: 1046–1049. For further details of his appointment to UCL, see Hi m s w o rth H. (1982) T h o m a s
L ewis and the development of support for clinical re s e a rch. The Ph a ros of Alpha Omega Al p h a 4 5: 15–19. Dru ry A
N, Grant R T. (1945–48) Sir Thomas Lewis. Ob i t u a ry Notices of Fe l l ows of the Royal Society 5: 179–202. A collection
of his papers, CMAC / P P / L EW, is held in the Contemporary Medical Arc h i ves Centre of the Wellcome Library.
71 Booth C C. (1987) Doctors in Science and Society: Essays of a clinical scientist. London: British Medical Journal.
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an attitude that existed, as Stan Peart pointed out in the London schools at that time.
It is interesting too, that the Dean of that school wrote a letter to Harry Himsworth,
which I have read, saying that it was virtually impossible to get a new director
employed by the MRC. Robert Platt, then a close adviser to Sir Harold [Himsworth],
had tried to find a successor, suggested two of his young men. The Dean replied, ‘One
has too much personality, the other too little’. I won’t tell you who those two young
men are, but one of them is sitting two seats to the right of me right now [Sir Douglas
Black]. [Much laughter] The other side of this relates to Stan Peart’s appointment as
Professor at Mary’s, because the Dean at Guy’s said it had been very difficult to find a
successor to George Pickering at St Mary’s, and they had finished up appointing a
mere pharmacologist. [Much laughter] There was throughout London a very serious
resistance to academic medicine. I don’t think it changed until after the 1970s. 
Professor Eric Bywaters:72 I might just confess that while I was at Hammersmith
(and I had chosen Hammersmith because there was no other place on coming back
from the MGH [Massachusetts General Hospital] before the war), I put in for the
Chair of Medicine at Middlesex Hospital. It was very interesting, because when I
enquired I found that all I was allowed was a desk in Sister’s office, no labs, because
they were already provided, of course, by the Courtauld (Dodds),73 and the Bland
Sutton Institute (Whitby)74 and so on. I didn’t go further than that.
Walton: Thank you. T h a t’s a ve ry important point, because as you say it took a ve ry long
time for many of the medical schools to get around to appointing full-time chairs; indeed,
in the medical school [King’s College, Un i versity of Durham] where I was trained, there
we re laboratories for all the pre clinical disciplines, and for pathology and micro b i o l o g y,
but there we re no laboratories for any of the clinical disciplines in a medical school
building opened in 1938. That was the kind of atmosphere that existed at that time.
Guz: Very briefly. I wanted to get back to this issue of the University and Northwick
Park. The University didn’t feature at Northwick Park (and we have spoken about
72 Professor Eric Bywaters CBE FRCP (b. 1910) was Professor of Rheumatology at the Royal Postgraduate Medical
School, Hammersmith Hospital, London, from 1958 to 1975, later Emeritus, and Consultant Physician at the
Hammersmith Hospital, London, and Wexham Pa rk Hospital, Slough, Bucks. He was Di rector of the MRC Rheumatism
Re s e a rch Unit, Ta p l ow, from 1958 to 1975. He wrote: ‘I would like to add a statement about the aid given by the MRC
and others to an independent Re s e a rch Unit at Ta p l ow (Canadian Red Cross Memorial Hospital). This [hospital] was
p resented to the nation at the end of the war by the Canadian Government for the study and tre a tment of juve n i l e
rheumatism in 1947. This was supported by the NHS in 1948 and by numerous charities. The MRC supported two posts
and then in 1958, took over the whole of the Special Re s e a rch Unit as well as building an animal house, library, lecture
room and work s h o p. This support continued from 1958 until its gradual closure from 1975 onwa rds. It led child re s e a rc h
firstly on rheumatic fever re s e a rch and later on juvenile chronic art h r i t i s .’ Letter to Dr Tilli Ta n s e y, 19 April 1999.
73 See Note 31.
74 Sir Lionel Whitby MC Kt CVO FRCP (1895–1956) was Regius Professor of Physic at Cambridge University
from 1945 until his death. He headed the Army Blood Transfusion Service from 1939 to 1945. His research at the
Bland Sutton Institute, London, focused on pathology, bacteriology and haematology and included collaborative
work that led to the development and successful production sulphapyridine (M&B693). See Whitby L E H,
Dodds E C. (1931) The Laboratory in Surgical Practice. London: Constable and Company Ltd. See Anonymous.
(1968) Sir Lionel Ernest Howard Whitby, Munk’s Roll 5: 444–445. For Dodds’ biographical note, see note 31.
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that). I wonder whether this was an active policy? I haven’t heard the genesis of this
stand offishness, but I do know one thing about the site of Northwick Park. I believe
the MRC bought the site from Charing Cross who had already bought the site.
Anyway Charing Cross was supposed to be there, all the plans were there. But the
University of London in the 1950s made a declaration that we couldn’t have a
university institution, a medical school, as far as that from Senate House, because the
site was a few hundred yards outside a geographical ring which was incorporated, or
defined, in the statutes of the University of London.75 And Charing Cross then,
immediately, had to get out and ended up where it did, between a lot of other hungry
hospitals. So I am just wondering whether there was some legalistic thing like that. It’s
absolutely extraordinary if you think about it now. Look how far St George’s is from
Senate House, and when you think that even at that time there was the direct line
from Northwick Park to Baker Street, so it was an absolutely extraordinary decision,
but I remember it well and what I am saying is absolutely correct.
Walton: Can anyone answer that question? No? May I, as an aside, ask whether my
recollection is at fault? Wasn’t there a suggestion at one stage that Charles Clore would
buy the marshalling yards next to Hammersmith and would erect a major centre to
incorporate all of the postgraduate institutes and hospitals in London in return for
their sites in central London? Can anyone remember when that was mooted?
Sir David Innes Williams:76 Well, it’s certainly correct. I can’t put a date on it, but I do
remember that amongst all the frustrated plans that we had concocted over the 1950s
and 1960s that never got anywhere at all, that was one of them. 
While I am speaking I would just like to say how glad I was that Sheila [Howarth]
mentioned the postgraduate institutes, because in them a good deal of clinical research
went on. Peter Williams just mentioned orthopaedics. Herbert Seddon77 throughout
that period was very interested in clinical research. As far as the Royal Colleges are
concerned there was the Royal College of Surgeons’ Institute of Basic Medical
75 Charing Cross Hospital, a vo l u n t a ry institution, bought the 46-acre site at No rthwick Pa rk in 1944 with the help
of the Un i versity Grants Committee and planned an 800-bed hospital. After 1948 and the creation of the Na t i o n a l
Health Se rvice, the Mi n i s t ry of Health took over the hospital and government restrictions on building we re imposed
owing to shortage of hard currency and building materials, later loosened to include the project in stages after 1955.
The following year the Un i versity Grants Committee applied a previously overlooked clause in their charter which
re q u i red all Schools of the Un i versity be within the administrative boundary of the County of London. Although
No rthwick Pa rk was said to be 20 minutes by underground from Piccadilly Circus, it was just outside the London
County Council boundaries. The Mi n i s t ry of Health took over No rthwick Pa rk and Charing Cross was offered a
site in Fulham. See Minney R J. (1967) The Two Pillars of Charing Cross: The story of a famous hospital. L o n d o n :
Cassell for the Board of Governors of Charing Cross Hospital, 204–208. See also Anonymous. (1956) New
academic year: Charing Cross Hospital, Fu t u re Site of Medical School. British Medical Jo u rn a l i i: 821–822.
76 Sir David Innes Williams FRCS (b. 1919) was Urological Surgeon at St Peter’s Hospital, London, from 1950 to
1978 and at the Hospital for Sick Children, Great Ormond Street, from 1952 to 1968. He was Director of the
British Postgraduate Medical Federation from 1978 to 1986, Chairman of the Council of the Imperial Cancer
Research Fund, and President of the British Medical Association from 1988 to 1989 and of the Royal Society of
Medicine from 1990 to 1992.
77 See note 36.
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Sciences, in which Bill Paton and [Eleanor] Zaimis did their first work, followed by
John Vane,78 who made a considerable contribution. I think there’s no doubt that the
Colleges were remiss over the years in failing to promote research. 
The Imperial Cancer Research Fund (ICRF), of course, was set up by the two Colleges
in 1902, originally with the idea that it would do clinical research. It went straight
over into laboratory work. In the 1920s, the British Empire Cancer Campaign, led by
Lockhart-Mummery,79 split off in order to make the research clinical. Cuthbert
Dukes’ work at St Mark’s80 was supported by the British Empire Cancer Campaign
over a long while. It did very good work. ICRF of itself remained laboratory based
until quite late on, substantially into the 1970s and 1980s.81
Professor John Dickinson:82 It seems to me we are being awfully coy about money,
because unfortunately money and prestige seem to go together. I recall very clearly my
surgical chief, Julian Taylor, who was the immediate disciple of Wilfred Trotter,83
saying to me in reference to a certain professor of medicine and professor of surgery,
‘Well, of course, he was appointed when professors of medicine were second-class and
professors of surgery fourth-class.’ And I think we haven’t really mentioned the
absolute total dominance of Harley Street which I remember, even at UCH, which
was supposed in the 1950s to be a rather academic sort of hospital,84 and the scorn in
which academics of all sorts were held by the rest of the staff. I think one of the reasons
why the provincial medical schools did much better in academic standing at that time
was the fact that they didn’t have Harley Street next door.
Walton: I am sure that was a factor, and yet at the same time even in some of the
provincial medical schools there was a problem about what was meant by clinical
research. I recall clearly that when I became involved in the early years of establishing
a charity for the Muscular Dystrophy Group and we were at that time collecting
78 Sir William Paton Kt CBE FRCP FRS (1917–1993) was Professor of Pharmacology at the University of Oxford
from 1959 until his retirement in 1983, having been on the staff of the NIMR from 1944 to 1952. He was a
member of the MRC from 1963 to 1967 and a Trustee of the Wellcome Trust from 1978 to 1987. Professor
Eleanor Zaimis (1915–1982) was Professor of Pharmacology in the University of London at the Royal Free
Hospital School of Medicine from 1958 to 1980, later Emeritus. Sir John Vane (b. 1927), pharmacologist,
discovered the role of prostaglandins in the human body in response to illness and stress. He shared the 1982
Nobel Prize for Physiology or Medicine with Sune Bergström and Bengt Samuelsson.
79 Mr John Percy Lockhart-Mummery FRCS FACS (1875–1957) was Consultant Surgeon to St Mark’s Hospital
for Diseases of the Rectum from 1903 to 1935, later Vice-President of the Hospital from 1940 to the introduction
of the NHS in 1948. He was a founder of the British Empire Cancer Campaign and the first Secretary of the
British Proctological Society in 1913. See also Granshaw L. (1985) St Ma rk’s Hospital, London: A social history of
a specialist hospital. London: Oxford Un i versity Pre s s .
8 0 Cu t h b e rt Dukes OBE FRCS FRC Path (1890–1977) was the first pathologist to St Ma rk’s Hospital, London,
in 1922 and to St Pe t e r’s Hospital in 1929. His achievements include a polyposis register and a classification
of bladder tumours. See Brunning D A, Dukes C E. (1965) The origin and early history of the Institute of
Cancer Re s e a rch of the Royal Cancer Hospital: Read at a meeting of the Section of the Hi s t o ry of Me d i c i n e
held on 7 October 1964. Proceedings of the Royal Society of Medicine Section of the Hi s t o ry of Me d i c i n e 5 8 :
33–36. See note 79.
81 See note 148.
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money and were looking for people to do research in neuromuscular disease. Among
those who we re on our re s e a rch advisory committee was a ve ry distinguished
p rovincial professor of medicine, who was a member of the Clinical Re s e a rch Board .
He was asked whether he was interested in embarking upon or in getting one of his
members of staff to embark upon a programme of re s e a rch. He wrote back to say that
he had a member of staff who was writing up a family of patients with pero n e a l
muscular atrophy and if he had any difficulty in getting funds to buy his reprints he
would come back to us. It took a long time even to educate some of the clinical
p rofessors who had been brought up in the kind of clinical background you are
talking about. 
Can I go back to a point that was raised by Sheila Howarth? We all recognize that in
those days, up to the 1970s, if you got a research grant from whatever source, you had
no difficulty in recruiting bright young people of registrar status to undertake
programmes of clinical research because you could then get them honorary clinical
registrarships with no trouble and it made no difference to their ultimate career. When
did the problem begin to arise relating to the work of the JCHMT [Joint Committee
on Higher Medical Training] and all of the other problems of manpower planning
that made this so difficult? I know that the whole question of registrar numbers,
training numbers, is only very recent, but when did people begin to feel that there was
a difficulty in getting that honorary status for people who were doing research? That
was not in the 1970s was it?
Innes Williams: Much later, after the Department’s paper, ‘Achieving a Balance’.85
82 Professor John Dickinson FRCP (b. 1927) was trained at Oxford and Un i versity College Hospital, London, and
appointed Physician at UCH in 1964, then Professor of Medicine at St Ba rt h o l o m ew’s Hospital Medical College,
London, from 1974 to 1992. He is now Emeritus Visiting Professor at the Wolfson Institute of Pre ve n t i ve Me d i c i n e .
He has been a member of the MRC, Chairman of the British Medical Re s e a rch So c i e t y, Se c re t a ry of the Eu ro p e a n
Society for Clinical In vestigation. He retains a strong interest in clinical re s e a rch and in the aetiology of diseases.
83 Professor Wi l f red Trotter FRCS FRS (1872–1939) was Di rector of the Surgical Unit at Un i versity College
Hospital, London, with the title of Professor of Su r g e ry from 1935 to 1938 and a Fe l l ow of Un i versity College.
He was a member of the MRC from 1929 to 1933. He was Se r j e a n t - Surgeon from 1932 until 1939, having
s e rved King George V, King Ed w a rd VIII and King George VI. Trotter was also interested in the
p h y s i o p s ychological aspects of pain.
84 Dr Derek Bangham wrote: ‘Staff at UCH were indeed active in research. Before the war there were, I think, at
least three professors. While I was there during the 1940s and 1950s there were about eight FRS: Sir Thomas
Lewis, Sir Gordon Cameron, Sir Charles Harington, Sir Francis Walshe, Sir Ashley Miles, CE Dent, Claude
Rimington, Wilson Smith. E E Pochin (later Sir Edward) succeeded Lewis, bringing to UCH some of the first
users of radioisotopes (I131) for clinical research. Sir Harold Himsworth and Lord Rosenheim and several others
on the staff were, later, made FRS.’ Letter to Mrs Lois Reynolds, 20 April 1999.
85 Department of Health and Social Security. (1986) Hospital Medical Staffing: Achieving a balance: A consultative
document, July 1986, and its follow up (Newton T. (1987) Hospital Medical Staffing: Achieving a balance – plan for
action, Steering group for implementation. London: HMSO) introduced the concept of a ‘safety net’, a minimum
safe level of staffing, of junior doctors in the acute specialities. Sir David Innes Williams wrote: ‘In essence it set
the pattern for a restriction in the numbers of approved training registrar and senior registrar posts to bring them
into line with expected consultant vacancies. It thus curtailed the ability of clinical academic units to recruit
research-oriented staff while at the same time it failed to address the plight of large numbers of doctors in the
Senior House Officer grade who could not progress upwards.’ Letter to Mrs Lois Reynolds, 4 April 2000.
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Walton: ‘Achieving a Balance’ was the thing that did it. In the mid-1980s really.
Tyrrell: I’d like to go back to the point when you raised ‘white-hot technology’,86
because I think it comes as a contrast to what we have been hearing about the attitudes
to funding and support in hospitals. I remember a similar conversation with Sir
Harold Himsworth, in which he said that when the Labour Government was in power
he was much more warmly received when he came to ask for extra money for
additional projects which the MRC had in mind. There may have been a contrast in
his experience in that respect, which is worth including as a minor point.
Wa l t o n : Thank you. I recall that Shirley Williams came to talk to the Medical Re s e a rc h
Council, I think it was in Jim Gow a n s’ time.8 7 A f t e rw a rds, because the members of
Council we re so polite she went to the Chairman, then the Duke of No rt h u m b e r l a n d ,
and said, ‘I don’t think much of that Council.’ It seems that she thought we we re too
polite and not sufficiently abrasive in our attitude to government policies.
Lachmann: If I may make three points. The first goes back to Northwick Park. I was
never a member of Northwick Park staff, but I might have been, had John Squire not
died.88 I noticed that in all this discussion of Northwick Park John Squire’s name has
not yet been mentioned and he was formulating the programmes when  unfortunately
he dropped dead, at a rather critical moment. I think that the way Northwick Park
developed was more affected by John Squire’s death than is often realized. And the
second, returning to the point that Bill Hoffenberg made about Northwick Park, is
Maurice Pappworth, another who has not been mentioned. It was, of course, just
about the time that Northwick Park was being founded that Maurice Pappworth
wrote his book, Human Guinea Pigs, which got enormous press coverage at the time.89
I think again there is no doubt that that played a considerable part in the reluctance
of the non-MRC staff at Northwick Park to recruit those who might be regarded in
Pappworth terms as ‘human experimenters’. 
Can I make a third point, on the question of how to define clinical research.90 As a
pathologist I get the impression that clinical research is given a slightly more restrictive
86 See note 45.
8 7 Sir James Gowans Kt CBE FRCP FMedSci FRS (b. 1924) was Se c re t a ry of the MRC from 1977 to 1987, having
been a member of the Council from 1965 to 1969. He had previously been the first Ho n o r a ry Di rector of the MRC
Cellular Immunology Unit at the Sir William Dunn School of Pathology of the Un i versity of Oxford from 1963 to
1977. From 1989 to 1993 he was Se c re t a ry General of the Human Frontier Science Programme in St r a s b o u r g .
88 Professor John Squire FRCP (1915–1966) was Director-Designate of the Clinical Research Centre at Northwick
Park Hospital, Harrow, during the planning period from its announcement in July 1960 to his sudden death in
1966. He had directed two other MRC Units in Birmingham: the Industrial Medicine Research Unit from 1946
to 1952 and the Unit for Research on the Experimental Pathology of the Skin from 1952 to 1962. See Arnott W
M. (1984) John Rupert Squire. Munk’s Roll 7: 412–413.
89 Pappworth M H. (1967) Human Guinea Pigs: Experimentation on man. London: Routledge & Kegan Paul. See
Booth C. (1994) M H Pappworth, MD, FRCP. British Medical Journal 309: 1577.
90 See box on page 7.
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definition here than the one I would use. I have used the definition in the past that
‘clinical re s e a rch is re s e a rch that uses patients as a re s o u rc e’. I think pathologists who do
re s e a rch on bits of patients are just as much doing clinical re s e a rch as people who are
w o rking by the bedside, and that there was quite a lot of clinical re s e a rch going on eve n
in places which didn’t have much frankly patient-directed re s e a rch even as early as the
1950s. I was a student when John Dickinson was RMO (Resident Medical Officer) at
UCH and my view of the attitude there to academic re s e a rch in the 1950s was much
m o re positive. I was Charles De n t’s houseman,9 1 and certainly in the heart of the medical
unit at UCH there was an extremely positive atmosphere for doing clinical re s e a rc h .
Walton: I think that’s a very important point; one must recognize the tremendous
inspirational influence of teachers and research workers upon the career development
of individuals. One of my great teachers was James Spence, whose name has already
been mentioned. I remember him saying, and I have always quoted it, ‘You never
know anything about a disease until you look at it’. You really have got to look at it
in depth, and investigate it before you understand its mechanisms. 
Scadding: To add to what Peter Lachmann has said about the range of clinical research,
I should extend it to include clinically applicable research on populations. Some of the
most important projects on common diseases that the MRC has supported have been
based on populations. As examples, I would mention the Doll92 and Hill93 studies of
the effects of tobacco smoking,94 starting from a concern with the rising incidence of
lung cancer and resulting in the demonstration that smoking is not only the principal
cause of this, but also an important factor in some other common respiratory and
cardiac diseases. Also the work of the Pneumoconiosis Unit in South Wales, under
Charles Fletcher95 and John Gilson, which elucidated the complicated relationship
between coal-dust exposure and the incidence and progression of coal miners’
91 Watson L. (1984) Charles Dent (1911–1976). Munk’s Roll 7: 148–149. See also note 84.
92 Professor Sir Richard Doll Kt CH OBE FRCP F MedSci FRS (b. 1912) was Regius Professor of Medicine at the
University of Oxford from 1969 to 1979, later Emeritus. He was Chairman of the Adverse Reaction
Subcommittee, Committee on Safety of Medicines, from 1970 to 1977 and has been Honorary Consultant to the
Imperial Cancer Research Fund Cancer Studies Unit, Radcliffe Infirmary, Oxford, since 1983.
93 Sir Austin Bradford Hill CBE Kt FRS (1897–1991) was Professor of Medical Statistics at the London School of
Hygiene and Tropical Medicine from 1945 until 1961. Doll R. (1994) Austin Bradford Hill. Biographical Memoirs
of Fellows of the Royal Society 40: 128–140.
94 Doll R, Hill A B. (1950) Smoking and carcinoma of the lung: Preliminary report. British Medical Journal ii:
739–748. See also Doll R. (1998) The first reports on smoking and lung cancer, in Lock S, Reynolds L A, Tansey
E M (eds) (1998) Ashes to Ashes: The history of smoking and health. Amsterdam: Editions Rodopi BV, 130–142. 
9 5 Professor Charles Fletcher CBE FRCP (1911–1995) was Professor of Clinical Epidemiology at the Roy a l
Postgraduate Medical School, Hammersmith Hospital, London, from 1973 to 1976, later Emeritus, and Ph y s i c i a n
to Hammersmith Hospital from 1952 to 1976. He directed the MRC Pneumoconiosis Re s e a rch Unit from 1945 to
1952 and was Se c re t a ry of the MRC Committee on Bronchial Re s e a rch from 1954 to 1976. He was a member of
the Council of the Royal College of Physicians from 1959 to 1963 and Se c re t a ry to their Committee on Sm o k i n g
and Health from 1961 to 1967. See Fletcher C. (1998) The story of the Re p o rts on Smoking and Health by the Roy a l
College of Physicians, in Lock S, Reynolds L A, Tansey E M. (eds), op. cit. note 94, 202–206. See also a videotape
i n t e rv i ew with Professor Charles Fletcher by Max Blythe, held at the Royal College of Physicians of London.
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pneumoconiosis.96 I would also mention Charles Fletcher’s long-term prospective
study of respiratory symptoms in a defined working population which provided
valuable insights into the pathogenesis and progression of the common condition,
which used to be labeled chronic bronchitis and emphysema, but is now more
appropriately called chronic obstructive pulmonary disease.
Multicentre controlled therapeutic trials have become an important feature of medical
research in the period we are considering. In the development of these, the trials of
s t re p t o m ycin in tuberc u l o s i s ,9 7 f o l l owed by linked comparative trials with
combinations of anti-mycobacterial drugs, coordinated by Philip D’Arcy Hart’s
Tuberculosis Research Unit, blazed the trail.98 And this Unit’s nationwide study of the
effectiveness of the BCG vaccination was the best-designed and most informative
investigation of this complex problem.99
If I may refer back to Stanley Peart’s comment; I think he must have been a little
unlucky at St Mary’s, because not all teaching hospital consultants were unhelpful. I
had the responsibility from 1946 onwards of trying to develop an academic institute
at the Brompton Hospital, renowned at that time only for its clinical expertise. I
found a wide range of willingness to cooperate among my clinical colleagues, from
some who understood what it was all about and were very helpful, to others who
regarded the new academic institute as a nuisance which stopped them running their
own hospital in the manner to which they had become accustomed and did their best
to ignore it. I think it was much the same in other hospitals. 
Walton: Thank you. 
Peter Williams: I would like to refer to John McMichael and link him to the point
you made about the support of people in medical research by the Wellcome Trust.100
McMichael became a Wellcome Trustee in 1960 as successor to Sir Henry Dale. He
steered the Trust towards clinical research and on his initiative we started the Senior
Research Fellowships in Clinical Science scheme.101 I believe that scheme was seminal,
96 See D’Arcy Hart P, edited and annotated by E M Tansey. (1998) Chronic pulmonary disease in South Wales
coalmines: An eye-witness account of the MRC surveys (1937–1942). Social History of Medicine 11: 459–468. A
Witness Seminar on ‘The MRC Epidemiology Unit (South Wales)’ was held at the Wellcome Building on 23
March 1999 and is being prepared for publication, enhanced by additional interviews with key witnesses.
97 See also Tansey E M, Reynolds L A. (eds) (2000) Post Penicillin Antibiotics: From acceptance to resistance?
Wellcome Witnesses to Twentieth Century Medicine, vol. 6. London: Wellcome Trust.
98 Dr Philip D’Arcy Hart CBE FRCP F MedSci (b. 1900) trained in medicine at University College Hospital,
London, where he became a Consultant Physician. He was Director of the MRC Tuberculosis Research Unit from
1948 until his retirement in 1965.
99 See Bryder L. (1989) Tuberculosis and the MRC, in Austoker J, Bryder L. (eds) op. cit. note 49, 1–21, especially
14–17. See also Medical Research Council, Committee on the Standardization of Freeze-dried BCG Vaccine.
(1960) Freeze-dried BCG vaccine: Stability of the vaccine under different conditions of storage and persistence of
tuberculin sensitivity in schoolchildren after vaccination. Second Report. British Medical Journal ii: 979–986.
100 See note 7. For Sir John McMichael’s biographical footnote, see note 50.
101 For the origin of the Senior Re s e a rch Fe l l owships in Clinical Science that started in 1962, see note 7, 102–103. 
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if you look at what happened to these Fellows. We also did a lot for the basic sciences,
but I think that our interest in clinical research meant that a new source of funding
had become available and the part played by the Trust was therefore very important.
Wa l t o n : Was it within this era, 1950 to 1970, that the re s e a rch funding agencies, in
which I include the MRC and the Wellcome Trust and other bodies, began to prioritize
a reas of re s e a rch? Or did that come later? Was it a period in which, for example, the
M RC decided that it would wish to further re s e a rch in dentistry and osteoarthritis and
some other topics, where they felt that there was under-provision or even a lack of
re s e a rch workers? I think it began in the period 1960–1970 didn’t it? (F rom the
a u d i e n c e : No, much earlier.) So there was a difference of opinion, but such
prioritization was an important factor. It even allowed the MRC grants committees a
little latitude in being able to give grants at a lower mark in some of those high-priority
fields compared with some of those in low-priority fields. Is that right, John Gr a y ?
Gray: Yes. There had been some form of prioritization going back before I ever was
on the scene. The thing that rather formalized this was – I can’t remember the date –
when we changed the board structure, as has already been mentioned.102 And when
we changed the board structure, and had grants committees related to those boards,
this was rather formalized. The theory, not always kept in practice, was that the
committees marked the research on purely scientific grounds, and it was up to the
boards to modify this if they wished on the grounds of priority.
Walton: That came in about 1968, because I recall that was when I was first
appointed to Clinical Research Board Grants Committee No. 2. It then became the
Neurosciences Board Grants Committee later.103
Booth: Can we just answer your question about the MRC and directed re s e a rch because
right from the start the MRC was invo l ved in specific re s e a rch problems. T h o m a s
L ew i s’s work on soldier’s heart during the First World War is a ve ry good example of a
d i rected piece of re s e a rc h .1 0 4 The second one is ve ry obviously the foundation of the
Pneumoconiosis Unit in Cardiff which was a response to public anxiety from the trade
unions, the ministry, and others, and they got the MRC to set that up.1 0 5 And the third
one obviously is Br a d f o rd Hill and Do l l’s work which was the result of a De p a rtment of
Health committee which was examining why there was an increasing pre valence of
cancer of the lung.1 0 6 So the MRC has always taken directed re s e a rch into account. 
102 See note 8.
103 See note 8.
104 Soldier’s heart was the disordered action of the heart due to neurosis, not organic abnormality. See Booth
(1989), note 49, 207. See also Lewis T. (1935) The Huxley lecture on clinical science within the university. British
Medical Journal i: 631–636. 
105 See note 96.
106 See note 94.
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Walton: And the Tuberculosis Units as well.107
Hoffenberg: One of my early impressions when I came here in 1968 concerned the
professor of medicine. In Cape Town he (it was always a ‘he’ in those days) was a god-
like figure, who had great power and dominated the hospital and the medical school.
When I arrived here and first experienced the internal workings of a major teaching
hospital in London I was astounded at the relatively small influence wielded by the
professor, who was simply one of a large number of consultants who made up the
clinical division. Whereas academic medicine was dominant in all specialties in Cape
Town, here other interests took priority.
The other point concerns the Clinical Research Centre. Between the time it was
planned and its opening a distinct change had taken place in the nature of research.
For instance, there were observation wards throughout the research wing, the purpose
of which was to allow patients to be observed and studied. And there were metabolic
wards for long-term collection of excreta, etc. Neither of these facilities was much used
because, by the time the CRC opened, new methods of clinical research had been
introduced that depended less on direct patient study and more on sophisticated
laboratory investigation. Peter Lachmann is right in attributing this change partly to
the Pappworth effect,108 but I believe there was a fundamental change in the way
research was carried out as measurement technology developed.
Walton: Thank you. The point that you made at the beginning is of course very
relevant;  many years ago I remember at Queen Square on a ward round with a fine
clinician, Charles Symonds,109 with whom it was possible to have a very fierce, and at
times immensely enjoyable, discussion about diagnosis and management. On the
ward round there was a young lady doctor from Hungary, who listened to the
arguments with increasing interest and extraordinary concern; she said, ‘We never
have arguments like this in our country. Don’t you have a professor?’ 
H i m swo rt h : Can I pick up on one thing which Peter Lachmann said about John Sq u i re
and the concept of clinical re s e a rch which was, I think, underpinning the Clinical
Re s e a rch Centre. Just to remind you that after John Sq u i re died, Graham Bu l l1 1 0 w a s
appointed dire c t o r, but his deputy director was Richard Doll and there was a ve ry
definite feeling that epidemiology was a large dimension in what should be done there .
107 See Fox W, Ellard G A, Mitchison D A. (1999) Studies on the treatment of tuberculosis undertaken by the
British MRC Tuberculosis Units, 1946–1986, with relevant subsequent publications. International Journal of
Tuberculosis and Lung Disease 3: S231–S279.
108 See note 89.
109 Sir Charles Symonds KBE CB FRCP (1890–1978) was at Gu y’s Hospital, London, from 1920, later as
Consultant Physician for Ne rvous Diseases, and on the staff of the National Hospital, Queen Sq u a re, London (later
the National Hospital for Ne rvous Diseases) as Consultant in Ne u rology from 1926 and until his re t i rement. He
assisted Sir Hugh Cairns in organizing the hospital for head injuries at St Hu g h’s College Oxford during the Se c o n d
World Wa r. See Wolstenholme G, Lu n i ewska V. (1984) Sir Charles Putnam Symonds. Mu n k’s Ro l l 7: 563–565.
110 See note 53.
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Professor Leslie Collier:111 Before we break for tea I should like to hear something
about the establishment of the MRC Laboratories in West Africa. I see that two of the
people concerned are here – Peter Williams and Brandon Lush. My own involvement
was as Honorary Director of the Medical Research Council’s Trachoma Unit, which
was attached to the MRC station in The Gambia for 12 years from 1956 to 1972. I
should like to hear something of the story of how that station was set up and
particularly its relationship with the Wellcome Trust, which made important financial
contributions.
Walton: Yes, what led to the establishment of these overseas MRC Laboratories and
how were they set up? What led also to the fact that the Wellcome Trust gave priority
to tropical medicine among its other programmes? So who would like to comment?
Lush: I think I am right in saying that it was the late B S Platt’s112 feeling that there
should be a field station for research on human nutrition that really led the Council
to consider setting up a station in the tropics, and so Ian McGregor was appointed as
Director113 and Leslie Collier, as he said, for the Trachoma Research Unit, which was
in the same grounds as the field station.114
Scadding: An obvious reason for locating a research group overseas is that that is where
the disease is. But this is not the only reason. The series of MRC studies which
established optimal regimens of treatment for tuberculosis illustrates this. As this
disease started to come under control in this country, it became difficult to run
1 1 1 Professor Leslie Collier FRCP FRC Path (b. 1921) was Professor of Vi ro l o g y, Un i versity of London, from 1966 to 1986,
later Emeritus, and has been Consulting Pathologist at the Royal London Hospital (formerly the London Hospital) since
1987. He joined the Lister Institute of Pre ve n t i ve Medicine in 1948, where he was Head of the De p a rtment of Vi ro l o g y
f rom 1955 to 1974, Deputy Di re c t o r, later Di rector of the Vaccines and Sera Laboratories from 1974 to 1978 and
Ho n o r a ry Di rector of the MRC Trachoma Unit from 1957 to 1973. He was joint Editor with M T Pa rker of the 8th
e d n of Topley and Wilson’s Principles of Bacteriology, Virology and Immunity (London: Edward Arnold, 1990) and
Editor in Chief of the 9th edn now Topley and Wi l s o n s’ Mi c robes and Mi c robial In f e c t i o n s (London: Arnold, 1998). 
112 Professor Benjamin Platt CMG (1903–1969) was Professor of Nutrition and head of the Department of
Human Nutrition at the London School of Hygiene and Tropical Medicine. He joined the MRC staff in 1938
becoming Director of the Human Nutrition Unit at the School in 1944. He was instrumental in setting up the
Unit’s field research station, which became the MRC Laboratories in The Gambia. He was a member of the
Tropical Medicine Research Board. See Platt B S. (1962) Tables of representative values of foods commonly used
in tropical countries. MRC Special Report Series 302: 1–46. 
113 Sir Ian McGregor Kt CBE FRS (b. 1922) was Director of the MRC Laboratories in The Gambia from 1954
to 1974, and 1978 to 1980 and Visiting Professor at the Department of Tropical Medicine at the Liverpool School
of Tropical Medicine from 1981 to 1994. He had been a member of the scientific staff of the Human Nutrition
Research Unit in The Gambia from 1949 until 1953. He returned to the National Institute for Medical Research
in 1974 as Head of the Laboratory of Tropical Community Studies until 1977. He was a member of the MRC
Tropical Medical Research Board from 1975 to 1977 and from 1981 to 1983.
114 The MRC Laboratories, The Gambia, was the new name of the Human Nutrition Research Unit at Fajara, with
a field station in Keneba, following a report of a subcommittee of Major-General Sir John Taylor, Brigadier J S K
(later Sir John) Boyd and A L (later Sir Landsborough) Thomson sent by MRC in 1952. Dr J Newsome was
Director, followed by Dr I A McGregor in 1954, and the Laboratories dealt with questions on malaria, including
entomological studies. A small section of the Trachoma Unit was attached to the Laboratories from 1958 but
directed from the unit’s headquarters at the Lister Institute. See Thomson (1975), note 29, 217–219.
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controlled trials here; so the latter part of this important series of linked studies was
conducted in India, Africa and Hong Kong. An important advantage of these
locations was that the procedures studied were selected with some regard to the social
and economic circumstances of the affected populations.1 1 5 I would mention
especially the Madras Tuberculosis Chemotherapy Research Unit directed by Wallace
Fox,116 which made a special contribution by training Indian counterpart workers,
who eventually took over its direction.
Peter Williams: When I worked at the MRC between 1956 and 1959 I was asked by
Harry Himsworth to understudy him in tropical medicine. Sir Harold was Chairman
of the Colonial Medical Research Committee of the Colonial Office and Dr Raymond
Lewthwaite117 was the Secretary. So all the tropical research of the Colonial Office  and
the MRC came across my desk. Himsworth came to the conclusion that the Colonial
Office structure was not suitable to be responsible for medical research in the colonies.
He took a broader view of the opportunities than those concerned with the classical
tropical diseases. He went on to define his view as medicine in the tropics, rather than
tropical medicine.
The story behind the trachoma research is a very fascinating one.118 Inclusion bodies
had been found in patients with trachoma and a man named T’ang in China had
cultured these. Professor E T C Spooner,119 Dean of the London School of Tropical
Medicine had brought a culture back from China. It became obvious that there was
an important opportunity available to develop knowledge of this important eye
115 A Witness Seminar, ‘British Contributions to Medicine in Africa after the Second World War’, was held at the
Wellcome Building on 3 June 1999 and is being prepared for publication.
116 Professor Wallace Fox CMG FRCP (b. 1920) was a member of the scientific staff of the MRC Tuberculosis and
Chest Diseases Unit at the Brompton Hospital, London, from 1952 until 1956 and from 1961 to 1965, becoming
Director of the MRC Tuberculosis and Chest Diseases Unit and Honorary Consultant Physician from 1965 to
1986. While seconded to the WHO he established and directed the Tuberculosis Chemotherapy Centre in Madras
from 1956 to 1961. 
117 Dr Raymond Lewthwaite CMG OBE FRCP (1894–1972) was Medical Research Adviser at the Ministry of
Overseas Development from 1964 to 1968. He had been a pathologist in Malaya in 1926, and field director of
the MRC’s Scrub-typhus Commission, South East Asia Command, from 1944 to 1945. He was appointed
Director of Colonial Medical Research at the Colonial Office from 1949 and acted as assessor to the MRC’s
Tropical Medicine Research Board.
118 Professor Leslie Collier later amended the above account: ‘The trachoma agent was first isolated in 1957 by T’ a n g
in China. Teddy Spooner from the London School of Hygiene was visiting there in 1958 and at my request bro u g h t
home a sample, which the latter successfully propagated at the Lister Institute. Fu rther isolations we re then made
by Josef Sowa in The Gambia, where the Trachoma Re s e a rch Group (later Unit) had recently relocated from the
Middle East because of the unsettled situation there. By now, I had assumed the directorship of the Tr a c h o m a
Gro u p, (hitherto held by Sir St ew a rt Du k e - Elder). My colleagues and I proved the aetiological role of the isolates in
trachoma and developed these findings into a major re s e a rch programme on the micro b i o l o g y, clinical features and
epidemiology of trachoma and allied infections.’ Revised draft sent to Mrs Lois Reynolds, 8 May 1999.
119 Professor E T C Spooner FRCP (1904–1995) was Professor of Bacteriology and Immunology at the London
School of Hygiene and Tropical Medicine from 1947 to 1960 and Dean from 1960 to 1970. He was Director of
the Emergency Public Health Laboratory in Cambridge from 1943 to 1944, later Chairman of the Public Health
Laboratory Service Board from 1963 to 1972, Editor of the Journal of Hygiene from 1949 to 1955 and a member
of the MRC from 1953 to 1957.
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disease. A laboratory for trachoma re s e a rch existed in the Middle East but the
political situation made it unsuitable for work at that time. So somew h e re else was
sought. The MRC Laboratories in The Gambia was a real possibility and so a visiting
g roup went there to see if it was suitable. I believe Dr Collier was a member of that
visiting team. They found the inclusion bodies and we re able to culture the viru s ,
using T’ a n g’s methods, and this led on to the work of the Sowas on trachoma in T h e
Ga m b i a .1 2 0 The Wellcome Trust provided the funds to build the laboratory for the
trachoma unit.
The broader story of the MRC’s involvement in the tropics is best exemplified by the
nutrition units in Jamaica and Kampala, Uganda. These were really a result of
Himsworth becoming interested in the conditions he saw in East and West Africa, and
the West Indies. His initiative led to the setting up of Regional Research Councils
(Committees) in those parts of the world. As a result the MRC became much more
involved in research in the tropics and brought a rather different approach to bear
than the Colonial Office classical tropical medicine.
Walton: Yes, of course, and in addition Montgomery and Cruickshank in the
University of the West Indies121 not only looked at nutrition, but developed a major
interest in other things like tropical spastic paraplegia and a number of other topics
which really came out of that particular programme. 
G o rd o n : Can I just say two things. One is just to answer a question posed earlier: f o r
those who don’t know the will of He n ry Wellcome, the answer to why the Trust has
been invo l ved in tropical medicine from the ve ry early days is that the Will enjoins
the Trust to support re s e a rch relating to the health of mankind in the tropics and
e l s ew h e re and ‘in the tro p i c s’ comes first rather than the ‘e l s ew h e re’. The second is
that we are talking about who was responsible for re s e a rch, and I think there is a lot
of evidence that many bodies we re concerned about how this side of clinical re s e a rc h
was supported. We have in the Tru s t’s files – not even yet in the arc h i ves, I believe it
is still in an active grant file – the minutes of a meeting chaired by He n ry Dale in
1944, which was to look at the postwar needs of the medical services of the empire .
The vision that this meeting created was of a centre which would deal with the
medical needs of the empire and re s e a rch relating to it, based around this part of
London, with a re c o n s t ructed Hospital for Tropical Diseases, the London School of
Hygiene and indeed this building [the Wellcome Building], being some of the
laboratories and suchlike to support this activity. In the end, the Trust did something
else, but there we re a lot of people contemplating such a centre for tropical medicine
and re s e a rch. The list of names of people who we re at that meeting is worth looking
at – it was long.
120 Sowa S, Sowa J, Collier L H, Blyth W. (1965) Trachoma and allied infections in a Gambian village. MRC
Special Report Series 308: 1–88. 
121 Montgomery R D, Cruickshank E K, Robertson W D, McMenemey W H. (1964) Clinical and pathological
observations on Jamaican neuropathy: A report on 206 cases. Brain 87: 425–462.
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Booth: Just to say I would like to support very strongly Peter Lachmann’s definition
of clinical research. I too have the broad view of it that it should span the molecule,
on the one hand, with the community on the other, and spread across the whole. 
And Leslie Collier is a very good example of a man who made a very major
contribution to clinical research and clinical activity, working in a laboratory at the
Lister Institute. It was he who discovered the method of freeze-drying smallpox
vaccine122 for performing vaccinations, and of course that was the absolute basis of the
eradication programme, because before we had freeze-dried vaccine you couldn’t do
that programme. 
Walton: Thank you, and as you will see in the circulated paper on clinical research,123
you are in fact quoted as saying ‘clinical science today includes a wide range of
subjects, ranging from epidemiology to studies of individual patients in depth, and the
laboratory analysis of specimens or tissues’. So it’s there.
Gray: Just one word about why medicine in the tropics developed so much at that
time. It was purely an administrative one. After Harry [Himsworth] became Secretary
of the MRC, he automatically became Chairman of the Colonial Medical Research
Committee of the Colonial Office, run by what became the Ministry of Overseas
Development. He very rapidly developed its work and after negotiations a Tropical
Medicine Research Board (TMRB) was set up, managed by the MRC, with Harry as
chairman, with 50 per cent of the membership nominated by the MRC, and 50 per
cent by the Ministry of Overseas Development.124 Harry drove it. 
B l a c k : I would like to issue a warning against the taxonomy of re s e a rch. The Ro t h s c h i l d
re p o rt agonized over the difference between ‘basic’ and ‘a p p l i e d’ re s e a rch and Fred Da i n t o n
added the concept of ‘s t r a t e g i c’ re s e a rc h .1 2 5 This made for confusion, and did not help the
p romotion of re s e a rch. I agree with Peter Lachmann, that what matters is the validity of
re s e a rch, not the type of methodology used. Presented with information, Napoleon is said
to have asked two questions: ‘ Is it true?’ and ‘Is it useful?’ Re s e a rch should be judged by
these criteria, not by the type of methodology.1 2 6 End of gnomic statement.
122 Collier L H. (1955) The development of a stable smallpox vaccine. Journal of Hygiene 53: 76–101.
123 See box on page 7.
124 The Tropical Medicine Re s e a rch Board was set up on 15 July 1960 by the MRC to advise the Se c re t a ry of St a t e
for the Colonies on all medical re s e a rch funded from Colonial De velopment and We l f a re Funds (amended in 1964
to include funds from the newly created Mi n i s t ry of Overseas De velopment and the Colonial Office, which merged
with the Commonwealth Relations Office a year later), from the Exchequer or from MRC funds. The Chairman
was Sir Ha rold Hi m s w o rth with Professor A C Fr a zer as Vice-Chairman and Dr Brandon Lush as Se c re t a ry.
125 Sir Frederick Dainton (Lord Dainton of Hallam Moors from 1986) Kt FRS (1914–1997) was Dr Lee’s
Professor of Chemistry at Oxford University from 1970 to 1973 and Chairman of the University Grants
Committee from 1973 to 1978. He was Chancellor of Sheffield University from 1978 until his death. His report
on ‘The Future of the Research Council System’ was published along with Lord Rothschild’s report on ‘The
organisation and management of Government R&D’, and prefaced by a memorandum by the Government. The
Lord Privy Seal. (1971) A Framework for Government Research and Development. Cmnd 4814. London: HMSO.
126 See Comroe J H Jr, Dripps R D. (1976) Scientific basis for the support of biomedical science. S c i e n c e 1 9 2: 105–111.
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Dr Gordon Cook:1 2 7 I hadn’t re a l i zed that Sir Ha rold Hi m s w o rth had differe n t i a t e d
b e t ween the formal discipline of tropical medicine, and medicine in the tropics, which
was pointed out by Peter Williams. I think this is ve ry, ve ry pertinent indeed, and we do
h a ve to think of these as two ve ry separate are a s .1 2 8 My contact with the MRC in the
t ropics was of course Kampala with the Infantile Malnutrition Re s e a rch Unit, which was
at that time run by R A Mc C a n c e ,1 2 9 f rom whom I learnt an enormous amount.
Peter Williams: I must come back to the setting up of the TMRB, because in my last
year with the MRC in 1959 I was very involved with the negotiations that Himsworth
was having with the Colonial Office to incorporate the Colonial Medicine Research
Committee (CMRC) into the Council, as an additional board. As I said earlier,
Himsworth had become dissatisfied, because of the strong orientation towards insects
and parasites. He could see the clinical opportunity for a broader view from the new
universities in the tropics with good clinicians going out to work in them. He had a
tremendous battle with the Treasury and the Colonial Office, but eventually he won
and the Tropical Medicine Research Board was set up in the 1960s, after I left to join
the Wellcome Trust. The TMRB had a broader membership, which included people
who were not classical tropical doctors.130
Wa l t o n : Thank you so much. In the last hour and thre e - q u a rters, we have ranged
e x t remely widely over many of the developments that took place and many of the
p roblems that arose in the era between 1950 and 1980; after tea we will look at the
major difficulties and, of course, the enormous expansion that occurred betwe e n
1970 and 1980.
Dr Derek Bangham:131 Just to add to your list of MRC-directed research, some of it
laboratory, but much of it influencing clinical research, should one mention the
127 Dr Gordon Cook FRCP (b. 1932) has been a member of the History of Twentieth Century Medicine Group
since 1997. He was Senior Lecturer in Clinical Sciences at the London School of Hygiene and Tropical Medicine
and Honorary Consultant Physician at the Hospital for Tropical Diseases, London, from 1976 to 1997. He had
been Lecturer at Makerere University College, Uganda from 1963 to 1969, Professor of Medicine at the
Universities of Zambia from 1969 to 1974, of Riyadh from 1974 to 1975 and of Papua New Guinea from 1978
to 1981. He was a Senior Medical Officer at the headquarters of the MRC from 1974 to 1975. He was President
of the Royal Society of Tropical Medicine and Hygiene from 1993 to 1995.
128 See Cook G C (proposer), Warrell D A, Bryceson A D M (opposers). (1997) Debate on ‘Tropical medicine as
a formal discipline is dead and should be buried’ at the Royal Society of Tropical Medicine and Hygiene meeting
at Manson House, London, 17 October 1996. Transactions of the Royal Society of Tropical Medicine and Hygiene 91:
372–375.
129 Professor R A McCance CBE FRS (1898–1993) was Professor of Experimental Medicine at the University of
Cambridge from 1945 to 1966, later Emeritus. He directed the MRC’s Unit at Wuppertal in Germany from 1946
to 1949 and the MRC Infantile Malnutrition Research Unit at Mulago Hospital, Kampala, Uganda, from 1966
to 1968. See Widdowson E M. (1995) Robert Alexander McCance. Biographical Memoirs of the Fellows of the Royal
Society 41: 263–280.
130 See note 124. 
131 Dr Derek Bangham FRCP (b. 1924) was Head of the Division of Biological Standards at the NIMR from 1961
to 1972. He was later Head of the Hormones Division of the National Institute for Biological Standards and
Control (NIBSC) from 1972 to 1987.
Clinical Research in Britain
39
Radiobiological Research Unit, the origins of the PHLS, the origins of the Transfusion
Service and the origins of the MRC’s contribution to biological standardization
throughout the world for some 50 years? 
Walton: Indeed, and some of them, those initial MRC initiatives, eventually led to
free-standing organizations which have subsequently had an independent existence as
National Boards.132
Howarth: And also the input of the MRC into the Services research. The personnel
research committees for the Army and the Navy and their subcommittees I think still
go on. 
Walton: Sheila Howarth pointed out to me [during the tea break] that we have said
little about the seminal influence of that great physiologist, Sir Thomas Lewis. I think
it is important to re c o g n i ze that his approach using clinical physiology and
pathophysiology to investigate disease processes was something which had a very great
influence upon research in the UK and it is right that we should pay tribute to him.
And may I take the opportunity, Sheila, in thanking you for making available to me
a copy of the Cohen Report and the Memorandum HM(57)36 on clinical research in
the NHS.133 Now we come to the second session, 1970–1980. For the moment we
will defer looking at the Rothschild Report, and I am going to begin by asking Sir
Stanley Peart to comment upon his conception of the way in which research
developed during this decade and what were the problems that emerged. 
Peart: The points I want to make really revolve around a number of issues. The first:
you have heard me comment about the atmosphere in the medical schools in London
and that very much bears upon what actually happened to the Clinical Research
Centre. Because if I look at my own career, if I may use it, it has touched upon a
number of these issues. I was supported first by the MRC, hence my high regard for
the MRC, as a student in the department of pharmacology in Edinburgh with
Gaddum.134 At that time they were one of the few bodies which really offered support.
However, there were other bodies in existence of importance for clinical research, and
I would use a wide definition of clinical research. You can hardly escape noting the
132 Statutory boards took over the MRC’s administrative responsibility towards the Public Health Laboratory
Service (the Public Health Laboratory Service Act 1960), for the Radiological Protection Service (the Radiological
Protection Act 1970), and for the Biological Standards Board (the Biological Standards Act 1975) which operates
through the National Institute for Biological Standards and Control. Although the Blood Transfusion Service was
administered by the MRC during the Second World War, responsibility passed to the Ministry of Health with the
National Health Service Act 1946.
133 See note 16.
134 Sir John Gaddum Kt FRS (1900–1965) was Professor of Pharmacology at University College London from
1935 to 1938. In 1942 he accepted the Chair of Materia Medica in the University of Edinburgh until 1958, when
he became the Director of the Institute of Animal Physiology in Babraham, Cambridge, until 1965. He was a
member of the MRC from 1948 to 1951. See Feldberg W. (1967) John Henry Gaddum. Biographical Memoirs of
the Fellows of the Royal Society 13: 57–77.
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Beit Trust.135 The first name on the Beit Trust Fellowship list in 1910 was Sir Thomas
Lewis and he was then studying irregularities of the heart rhythm. You will see that
the Beit Fellowship from about 1910 to 1960 has got a reasonable smattering of
people who were engaged in clinical medicine as well as clinical research and research
applied to clinical outcomes. Here and there were some very prestigious names. The
first Professor of Medicine at University College, T R Elliott,136 was first responsible,
of course, for the concept of adrenaline being released from sympathetic nerve
endings, and many others after that, including Fred Sanger137 and others, whose
applications to clinical medicine, of course, are greater than most physicians. From
1970 onwards, the number of people with medical qualifications supported by the
Beit Trust dwindles to just about zero. Obviously, the Beit Trust doesn’t have the
money to support clinical salaries, so that’s a natural conclusion. 
Next, I was supported by the MRC to work in Mill Hill [NIMR], and the enthusiasm
gained by working in such an establishment which was based on the scientific breadth
of the people there, and their influence on clinical matters, is still there today. I think
of the outstanding people that were there. There was Archer Martin138 who introduced
amino-acid chromatography to the wide world, Rodney Porter139 working in the same
laboratory, responsible for the analysis of gammaglobulin. Wherever you looked there
were people whose contribution was without question, and how lucky was I to be
135 Sir Otto Beit KCMG FRS (1865–1930), British financier and philanthropist, was a Director of the British
South Africa Company and of Rhodesia Railways Ltd and a Trustee of the Rhodes Trust and of the Beit Railway
Trust for Rhodesia. He founded the Beit Memorial Fellowships for Medical Research in memory of his brother,
Alfred (1853–1906), the first of whom were appointed in 1909. See Tansey E M. (1994) The funding of medical
research before the MRC. Journal of the Royal Society of Medicine 87: 546–548. See also a collection of papers, the
Beit Memorial Fellowship, which is held as SA/BMF in the Contemporary Medical Archives Centre of the
Wellcome Library.
136 Professor T R Elliott CBE FRS (1877–1961) began at University College Hospital as Assistant Physician in
1910, the same year as he was awarded a Beit Fellowship. He was appointed to the first full-time MRC-supported
Chair of Clinical Medicine and Head of the Medical Unit at UCH in 1919, which he held until his retirement in
1939. He was a member of the MRC for three terms from 1920 to 1926 and 1939 to 1943. In 1936 he became
one of the original five Trustees of the will of Sir Henry Wellcome, which created the Wellcome Trust, and held
that office until 1955.
137 Dr Frederick Sanger OM CH CBE FMedSci FRS (b. 1918) was the first scientist to win two Nobel Prizes in
Chemistry. A member of the external scientific staff of the MRC in Cambridge in 1951, he joined the Unit for
Research on the Molecular Structure of Biological Systems (later the Molecular Biology Research Unit and from
1968 the MRC Laboratory of Molecular Biology), Cavendish Laboratory, University of Cambridge, and head of
a division from 1961 to 1983. He held a Beit Memorial Fellowship for Medical Research from 1944 to 1952. He
was awarded the Nobel Prize for Chemistry in 1958 for the structure of protein in insulin, and in 1980 for his
work on the structure of nucleic acids in DNA and RNA, which he shared with Paul Berg and Walter Gilbert.
138 Professor Archer Martin CBE FRS (b. 1910), biochemist, was a member of the scientific staff of the Medical
Research Council from 1948 to 1952, working at the Lister Institute of Preventive Medicine, then becoming Head
of the Physical Chemistry Division at the National Institute for Medical Research from 1952 to 1956. He became
Director of the Abbotsbury Laboratory, Consultant to the Wellcome Research Laboratories, at the University of
Sussex and Invited Professor of Chemistry at the Ecole Polytechnique at Lausanne, Switzerland. He shared the
1952 Nobel Prize for Chemistry with Richard Synge for their work on paper chromatography in 1944. 
139 Professor Rodney Porter FRS (1917–1985) was Whitley Professor of Biochemistry at Oxford University and
chairman of the department from 1967 until his death. Porter shared the Nobel Prize in Physiology or Medicine
in 1972 with Gerald M Edelman for their research on the chemical structure of antibodies. 
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there, and how lucky were other people like me who were exposed in that sort of way.
That convinced me, of course, that the right thing to do with any promising young
person was to make sure that they got into the right atmosphere. It doesn’t matter
whether it’s related immediately to the clinical work, what matters is the research of
the highest order.
Now I would pause on Northwick Park. You may think that I have had nothing to do
with Northwick Park at all. Well, I knew John Squire, who suggested to me that I
might like to go to Northwick Park and run one of the divisions of medicine. This
contributed, I’m afraid, to his early demise, because he dropped dead soon after that,
as befits a chain-smoker. But my interest in Northwick Park was considerable
although the flaws, compared with the medical school I happened to be in, as I saw
it, were considerable. Because even at that early stage I thought the plan of having that
type of hospital, that interaction, between the clinical services and the research services
didn’t seem to me as good as the medical school that I was in at the time. Now you
may find that odd, when I have complained about the atmosphere of London medical
schools. I think I am right to complain about the attitude of London medical schools,
because they did not encourage by their atmosphere the application of clinical
research. You had to fight very, very hard to pursue it. 
The first medical professorial appointment, soon after the First World War, to any
school was made at University College [London]. That was the first of the three which
were chosen.140 I have to introduce the name of Moran here,141 because he was a
remarkably far-seeing person. He fought very hard to have established at St Mary’s a
medical and a surgical unit in which research would be carried out. He had just
emerged from the trenches as a Regimental Medical Officer, and that’s a remarkable
achievement to think so widely from that background. He continued as Dean, which
is why George Pickering was appointed to the Chair at St Mary’s in 1939.
Lewis had enormous influence on the development of clinical research. Not just by his
personal achievements, but by attracting the people who would develop medical
research in the rest of the country. Among other things that I would like to draw your
attention to is the career support of people. 
We haven’t mentioned here the dual-support system. When I was at St Mary’s, early
on as a lecturer on the medical unit, I was aware that George Pickering used to go
away with three or four of his cronies on a visitation for the University Grants
Committee (UGC). They used to visit the universities and decide how the money
140 See Booth C C. (1993) Clinical research, in Bynum W F and Porter R. (eds) Companion Encyclopaedia of the
History of Medicine, vol. 1. London: Routledge, 205–229.
141 Charles McMoran Wilson (first Baron Moran of Manton from 1943) MC Kt FRCP (1882–1977) was
Consulting Physician, St Mary’s Hospital and Dean of St Mary’s Hospital Medical School from 1920 to 1945, and
President of the Royal College of Physicians from 1941 to 1950. See Lovell R. (1992) Churchill’s Doctor: A
biography of Lord Moran. London: Royal Society of Medicine Services. See also his autobiography, Moran C M W.
(1984) The Anatomy of Courage. London: Keynes Press for the British Medical Association. First published in 1945
by Constable and Company Ltd.  
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would be distributed. It was done on a ve ry ad hoc basis as I heard about it and it
was really re m a rkably imprecise. Like the relationships in medical schools betwe e n
the people running them and the source of money. It was ve ry imprecise. We we re
all used to a ‘knock for knock’ arrangement between the hospital and medical school
finances, which of course is banished now completely. The dual-support system,
which is disappearing, was one of the ways in which we could get away with ru n n i n g
medical units and clinical re s e a rch in the medical schools. T h e re was no problem, it
seemed to me, about being able to pick out people, get them supported one way or
a n o t h e r, without any thoughts about having to count the heads. One of the
p roblems for running a medical unit which one ought to concentrate on, is how can
you teach the medical students, run a good clinical service, and do re s e a rch of high
o rd e r. Nowadays you do not advise people to do that, it’s quite ridiculous to try and
get them to do all that, even if you have a unit of a ve ry large size. I have always
thought that the MRC units are models of how re s e a rch can be conducted in the
right sort of place. The unit system I think has still got a lot to teach us about how
to bring together the basic science and the clinical application in the right
a t m o s p h e re. I still believe it is one of the highlights of the MRC ’s contribution to
medical re s e a rch. 
Now the other body with which, of course, I have been associated since 1975 has been
the Wellcome Trust, and that has given me a very privileged position indeed, because
as the Wellcome Trust has grown it has become active in promoting areas that have
been neglected as far as we have seen, just as the MRC did. One of the tasks I was
given when I joined the Medical Research Council was to look at the possibility of
developing a centre for reproductive biology, in Britain. Our working party managed
to create that in Edinburgh142 with Baird, and Short (from Cambridge), and there you
had a very active role of the MRC which was not unique then, it was what they were
used to doing. Now the Wellcome Trust reacted in a similar way – in dermatology, in
mental health – bringing together the real excellence of neuroscience and psychiatry;
in ophthalmology, where the undoubted leading position of this country in visual
physiology was not matched by research in these and many other areas.143 I return
again to the way in which clinical research should prosper, which is by supporting
bright young people in the best possible way and there’s no doubt that the
contribution by the Wellcome Trust is the best thing that has happened for me and
for all the other members of the Trust. But it enabled the Trust to do a great deal to
ensure that clinical research could prosper by this career support. It saddens me
however as I reflect upon what’s happened over the last few years, because I have seen
how difficult it has become to pursue clinical research in the atmosphere of medical
schools. Why? The pressure of the National Health Service on beds, on positions,
142 MRC Unit on Reproductive Biology, University of Edinburgh, established in 1972 and directed by R V Short.
143 For details of additional support for neglected subjects, see note 100, 169–173, 276–304. See also Williams P
O. (1993) Extracts from the Annual Reports of the Wellcome Trust, 1960–1991, and Contemporary Lectures. 3 vols.
Wellcome Library.
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anything where you have to apply the lessons you learned from research to the care of
patients and their prospering, is blocked by the way in which the National Health
Service has regressed. Last year it was my privilege again to go round as an observer
for the Trust with the working party which looked at the possibility of providing
clinical research facilities in various of our university medical centres. For me the
wheel had turned full circle; from being able easily to run a medical unit previously,
in the heart of a medical school in London, we were now having to go and look at the
facilities which were desperately needed, I would have said, in practically all our major
teaching hospitals. They just were not there. And the Wellcome Trust was able to
provide facilities, buildings and equipment, to five centres.144 As far as I was
concerned, you could have made a strong case, and a strong case was made, for
another dozen. Now that is where clinical research has arrived at over the last 20 years,
which seems to me a great shame. There is no shortage of people as one looks at the
quality of those coming through both the MRC and the Wellcome Trust and all the
other research bodies, but we are at risk of not being able to provide them with the
right places in which they can pursue that clinical research.
Walton: Thank you very much, Stan, for that very interesting commentary. One of
the problems that we have always had in medical research has been to persuade people
working in the hospital service of the doctrine, or rather the aphorism, which is so easy
to prove, that today’s discovery in basic medical science brings tomorrow’s practical
development in patient care. And that’s not a message that many managers in our
health service are willing to accept. 
There are a number of points that I want to bring out relating to this decade of 1970
to 1980. One of them that I would like to look at in a moment is the question of the
change in the MRC board structure that took place from the Clinical Research Board,
on the one hand, to the vertical structure on the other, and the effect that that may
have had – good, or the reverse – upon clinical research. Then I want to look at the
issue of the Rothschild Report and its implementation and a number of other issues.
Perhaps I would just say in passing that in this decade it was not only evident to those
of us working in universities (for much of this decade, I was the Dean of a medical
school), that the MRC and the Wellcome Trust we re making an incre a s i n g
contribution, but so too were the other charities and foundations. 
The point that Stan Peart made about clinical support and the dual-support system,
which I had mentioned earlier, was a very crucial one, because one could at that stage
obtain from charities and even from private sources funds to endow chairs; when those
chairs were taken on to the University Grants Committee establishment, and when
144 The Wellcome Trust made five Millennial Awards for Clinical Research Facilities to medical schools in
Birmingham, Cambridge, Edinburgh, Manchester and Southampton in December 1997. The grants of £16
million covered construction costs for dedicated centres devoted to clinical research in collaboration with the
medical school and the area Hospital Trust. These awards coincided with the reforms to NHS funding proposed
by Professor Tony Culyer’s task force, whereby the centres would receive an agreed proportion of the earmarked
NHS funds to support recurrent clinical costs of research.
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s a l a ry increases we re subsequently approved, those salaries we re centrally
supplemented to the medical school of the university. That is something that
disappeared a long time ago. In the early 1980s the dual-support system began to
crumble for a variety of reasons. However, may I now turn to Abe Guz? I believe that
you were going to make a contribution at this stage?
Guz: I really just wanted to draw attention to an event, a very moving event of 1975.
The Ciba Foundation had a meeting, a symposium, on Health Care in a Changing
Setting: The UK experience,145 and for reasons not entirely clear to me I was chosen to
represent academic wisdom at the time and I remember at that time I was beginning
to feel the ‘winds of change’. Harold Macmillan had used that phrase on his visit to
South Africa during the 1960s, but it did seem to me that there was a chill appearing
in this whole thing. And I found that the most interesting thing was how I was
attacked in the nicest possible way by my colleagues for wanting to do what interested
me, rather than what the community thought was important. Now, I had the highest
respect for them, and they certainly put this view very clearly, but it was new to me.
For instance, I remember there were three major accusations at that time: that we were
neglecting vast areas such as clinical strategy, the strategy of screening, the risks of
diagnostic technology; that we were neglecting health services research; and finally,
that we were neglecting health policy, a relationship with ethics, medicine and law.
Now it was absolutely true that in the academic medical units which I had anything
to do with, these subjects were never even discussed, and that’s as recently as 1975. It’s
absolutely true. But of course I thought this was the inevitable result of the fact that
academic units were sort of small nidi implanted within the fairly big scene of the
National Health Service and you couldn’t do everything. So I did accept these
criticisms, but I was astonished at their intensity. So what I really wanted to say was
that at that time not only was specialism coming in in a very big way, but there were
these huge areas which cover vast fields, which academic units did not discuss.
Walton: Of course that was one of the points that led Rothschild to make the
recommendation that he did (Guz: I thought it was the most important point.) to the
effect that the Health Departments priorities, as defined by them, were not being
properly fulfilled in his view by the medical research structure as it then existed. So we
will come to that in a moment. But before we do, I wonder if John Gray would like
to comment upon what he saw as being the reasons for restructuring of the boards at
the MRC? What was the principal objective? Then we can ask people what they saw
as being the benefits and perhaps dis-benefits of that arrangement.
Gray: Well, I suppose like so many changes, it’s something entirely practical and
domestic which starts the whole operation going. Theory, and how it succeeded, was
something that followed later. The problem was that, with the increased number of
145 Guz A. (1976) The place of research, in Ciba Foundation, Health Care in a Changing Setting: The UK experience,
Ciba Foundation Symposium 43 (new series). Amsterdam: Elsevier, 129–141.
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applications, and the increased number of units to look after, etc., two boards couldn’t
handle the work. We had to have more boards. There was an easy and obvious division
in the old days between clinical and biological, but we had to start thinking again if
we were going to have three boards. There were suggestions about what a third board
might be when horizontally cut, but it made us think about it and some of us thought
that there would be real advantages in trying at the board level to bring together the
clinical work, with the sort of laboratory studies that underpin it. We have already
heard quite a bit about this today, about the advantages of having units, academic
units in medical schools, or MRC units where you’ve got the clinical people working
alongside biochemists or other people relevant to the work. It did seem to us, at least
in theory, that it would be good to have grants committees and boards organized on
what is often called the vertical system. You would have clinicians sitting round the
table with laboratory scientists. The clinicians would be able to say what the problems
are, and some of the things they come across, and listen to the things that were
interesting to physiologists and biochemists. You might get cross-fertilization and
you’d get cross-opinions in judging each case. So that is what we decided to do. We
went for the vertical, hoping this might increase the support for clinical research, but
this of course was a risk strategy, because by doing this it was always possible for the
boards to give too much weight to laboratory work. That was the basis.
Walton: Thank you. This was an era when, perhaps for the first time, clinical
academic units in the medical schools and universities began to exploit the advantage
of having whole-time basic scientists working, even on short-term research contracts,
within clinical departments. This was a very important development which was,
perhaps, helped by that particular policy.
Gordon: If I can follow on from that. The discussion whether you look after research
best by having boards in a horizontal structure or a vertical one is one we’ve been
through at the Trust as well and I can claim, in part, to being responsible for a change
at a slightly later era. When I joined the Trust there were a couple of committees,
notably one for tropical medicine, and the mental health panel that Stan [Peart] was
involved with setting up. The latter ran vertically, and the aim was to support research
in mental disorders. There were members going from social psychiatry, right through
to very basic neurobiology, sitting together. And that panel really seemed to work very
well. At the time that the Trust started to grow in the mid-1980s we introduced some
more panels and these ran horizontally, so we had the slightly uncomfortable position
of whether an application was in psychiatry or a closely related clinical subject, or was
it a biological neuroscience: such an application might go to one of three different
panels. And after some discussion in the late 1980s, we adjusted the panel structure
to an all-‘vertical’ one. The arguments were in part based on my own observation that
the vertically structured panels we had at that time seemed to work better than the
horizontal ones, because they didn’t get into quite such narrow conversations. Before
I wrote the paper proposing all-‘vertical’ panels, I did enquire within the MRC and I
found the last senior member of staff who could remember the old Clinical Research
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Board. I asked for his opinion, from the point of view of those within the MRC who
were handling the grants coming through, whether the loss of the Clinical Research
Board seemed to be an improvement or a disadvantage, and he felt that it probably
had been an improvement, because of the type of discussion at the Board that Sir John
Gray has alluded to. I would be fascinated to have other views on whether or not this
change was a good or a bad thing. If you all think it is a bad thing to have vertical
panels, I’ll retire gracefully.
Walton: Well, who would like to comment on the effects of the change in the board
structure and this, of course, was at a time, when quite apart from, as I said, the
Wellcome Trust, many of the disease-specific charities were beginning to have an
increasing influence in promoting research in the fields of interest related to their
particular diseases. So that was another things that influenced the position.
Ty rre l l : Yes, I would like to comment on the disease-specific charities, because I do
think that they do have a particular role. One of the most important roles that I
h a ve seen is the recognition that there is a real problem to be tackled. I saw it in
relation to sudden infant death syndrome [SIDS]. A wealthy businessman lost his
child and as a practical man in addition to grieving, he and his family decided to
s t a rt a foundation.1 4 6 In starting the foundation, they said they would spend half
their money dealing with the bereft parents and the other half would go into
re s e a rch, because they believed it was a real problem. At that time, many pare n t s
we re dealt with as criminals and there was a lot of argument as to whether there
really was a syndrome, or whether it was child neglect. They needed to put a small
re s e a rch group together themselves, because they couldn’t find any of the re s e a rc h
bodies, the big re s e a rch bodies, who we re pre p a red to take any interest. They start e d
a small group and I was privileged to be part of it and its work. For example, some
epidemiology was done, documenting cases that we re occurring in places like
Sheffield and in other parts of the country. The point that impinged on our pre s e n t
topic was that they thought it would be a good idea to go to the MRC and say they
had these data, that there are real problems and that they might be due to infection,
to re s p i r a t o ry disturbances, or immaturity at a physiological level, would the MRC
be interested to work on this? We had an informal meeting with members of the
b o a rd who said that the MRC did not work on nonexistent diseases. They had
decided that this wasn’t a real problem. It was there f o re ve ry good that the charity
went back to their office to find more funds to support more re s e a rch. It was, I
think, a sign that no human judgement is perfect. I don’t say the response was
necessarily a part of the board stru c t u re, but I think if the board stru c t u re had been
all there was, then nothing would have gone furt h e r. Howe ver because there was a
charity of concerned people who knew there was a problem, in spite of what other
e x p e rts said, they went ahead. Thus the re s e a rch to define the problem was actually
done, in spite of the flaws in the organization.
146 The Foundation for the Study of Infant Deaths.
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Walton: There are a number of other examples of situations in various specialities, not
least in my own field of neurology, where the existence of disease-specific charities has
made a major contribution to research. 
Professor Donald Munro:147 I would like to make some points relating to the
allocation of space for research in medical schools. Between 1950 and 1980 many
hospitals playing a major role in clinical teaching lacked any provision for their
academic staff and there was a particular shortage of laboratory space, even though
staff were required to be involved in clinical research. As the intake of medical
undergraduates has increased there were eventually agreed protocols recommended to
universities with clinical medical schools, which could be applied to the planning of
new academic buildings and thus ensure that proper opportunities were available to
both the academic staff, as well as make provision for those NHS staff who wished to
be involved in research.
In spite of the difficulties already discussed about the problems of traditionally
established routes for tertiary referrals, where such facilities were available, some
progress could be made in attracting staff who were able to exploit their earlier
research experience and continue to encourage their junior staff to be involved.
Innes Williams: Could I make a point about the disease-specific charities? The
Imperial Cancer Research Fund in the late 1970s was overflowing with funds and we
started to spend it on clinical units, in order to try to maintain some contact between
clinicians and the laboratory scientists in Lincoln’s Inn Fields.148 We endowed chairs
at Bart’s, at Guy’s, at Edinburgh and at Oxford, and a number of other units, but it
was actually quite difficult to maintain a relationship between the clinicians and the
laboratories. It seemed to break down again and again. We tried to supplement the
endowment, which was usually considerable, by a regular grant in order that we
should have some control over what went on in the units, much to the dismay of other
units in the medical school, and we continued to support the junior staff in those
units. However they were frequently diverted by the pressures from the clinicians to
provide clinical services and, as the NHS funding was reduced, we found ourselves
paying for regular clinical treatment and not for research at all. 
Walton: Thank you. That was certainly a major problem. The other thing that struck
me very powerfully was that in my own medical school [Newcastle], during the time
147 Professor Donald Munro MD FRCP (b. 1925) qualified at Aberdeen University in 1947. After house officer
posts he was Assistant Lecturer in Materia Medica in Aberdeen before serving as a junior specialist in medicine in
the Royal Army Medical Corps in Malaya between 1949 and 1951. After a further period in Aberdeen he became
Lecturer in Therapeutics in Sheffield in 1953, spent a year as Research Fellow in the Department of Medicine at
Tufts Medical School, Boston, MA, and after promotion to Senior Lecturer at the University of Sheffield, was
awarded a personal Chair in Endocrinology from 1967. When the Northern General Hospital became a
recognized teaching hospital in 1973, he was appointed Sir Arthur Hall Professor of Medicine with responsibilities
for planning the clinical sciences centre to accommodate the new academic departments. He has been Emeritus
Professor of Medicine since 1990.
148 Austoker J. (1988) A History of the Imperial Cancer Research Fund 1902–1986. Oxford: Oxford University Press.
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that I was Dean, through individuals who were very wealthy and charitably disposed,
we we re able to endow a certain number of chairs and readerships, often in what I would
call the tert i a ry, not the mainline, specialities. But we quickly learnt the lesson that to
e n d ow a so-called ‘naked chair’ without supporting staff was a mistake, because the
individual had then to go out and seek funding from other sources to employ the
s u p p o rting staff. But one thing which I thought was ve ry important was that we raised
money at that time to endow what we called lectureships in clinical science. These we re
l e c t u reships established to employ scientists within clinical departments; they we re
competed for throughout the entire faculty, so that departments had to decide who was
going to put up the best case for having such a lecture s h i p. I think that policy is
something that perhaps has not been followed up as well as it might; you all know of the
p roblems of the short-term re s e a rch grant employing scientists on successive thre e - ye a r
appointments, in clinical departments where there is no really good career stru c t u re, as
has been clearly indicated on many occasions. Ve ry little has been said about the board
s t ru c t u re. Would anyone wish to discuss that furt h e r, before we go on to Rothschild? 
If not, may I remind you that in 1971 two Government Green Papers were produced
on the organization and management of government R&D, one the Rothschild
Report on the future of the Research Council system, another the Dainton Report. It
was in 1972 that a White Paper introduced the customer–contractor principle,149 the
Rothschild Report, which as you know created the appointment of a Chief Scientist
at the Department of Health and Social Security (DHSS), the first appointee being
Dr Dick Cohen.150 Then, Sir Douglas, you followed in 1973, and Arthur Buller
followed in 1978. May we then ask Sir John Gray again to comment upon the
background to the introduction of the Rothschild mechanisms in the MRC?
Gray: The date of the Green Paper, 1971, marks the end of a long period. When I
became Secretary of the MRC in 1968 it was already clear that not only was there a
feeling in the Health Departments that they wanted more influence on the research
that the Council did, but much more widely it was clear that within the Government
as a whole the Research Council system was not entirely popular and was not along
their lines of thinking. I don’t want to go into the things that happened meanwhile,
but the first attack was on the Natural Environment Research Council (NERC) and
there were various other things. Inevitably we had all along a certain amount of
149 Lord Privy Seal. (1972) Framework for Government Research and Development. Cmnd 5046. London: HMSO.
The White Paper recommended the customer–contractor principle, embodied in the transfer of about one-third
of the research funds from three Research Councils – the Agricultural Research Council, the MRC and the Natural
Environment Research Council – to their customer departments; the appointment of a departmental Chief
Scientist with a supporting organisation, who would be a full member of the Research Councils; an improved
career structure for scientists within the Civil Service; and the reconstitution of the Council for Scientific Policy
(which later became the Advisory Board for the Research Councils).
150 Dr R H L Cohen CB MRCS (1907–1998) was on the staff of the MRC from 1948, serving as Deputy Chief
Medical Officer from 1957 to 1962, when he was seconded to the Ministry of Health as Principal Medical Officer
from 1962, Deputy Chief Medical Officer to Sir George Godber from 1967, and finally as the first Chief Scientist
to the Department from August 1972 until his retirement on 1 April 1973. See Wilson J M G. (1998) Richard
Cohen: First Chief Scientist at the DHSS. Journal of the Royal Society of Medicine 91: 222–224.
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rumour information about what the feelings were in various parts of the system.
Harold Wilson, at the end of his government, had set up an inquiry in the
Department of Agriculture, about the Agricultural Research Council (ARC), which
was thought to be a vulnerable case. A committee was set up under the chairmanship
of Paul Osmond.151 That report was completed towards the end of October 1970 (I
think I am getting my dates about right), and we knew that the recommendation was
going to be that the ARC should be abolished and all the work should be taken over
by the Ministry of Agriculture, Fisheries and Food (MAFF). 
T h e re was a dramatic moment in all this, which I think I should relate. One morning
in that month I had a telephone call, and so did the other chief exe c u t i ves of Re s e a rc h
Councils and the Chairman of what was then called the Council for Scientific Po l i c y
(CSP), (F rom the floor: ‘The CSP - that was a predecessor of what is now the Ad v i s o ry
B o a rd for the Re s e a rch Councils (ABRC), or which later became the ABRC; it doesn’t
exist now, but theoretically it had more powers; it is now the Office of Science and
Technology and is in the De p a rtment of Trade and In d u s t ry) to go immediately to the
De p a rtment of Education and Science. It was the CSP which used to distribute the
grants between the Re s e a rch Councils and Fred Dainton was at that time the chairman.
We we re summoned to this meeting, and the reason we we re summoned was that the
issue was coming to Cabinet the next day and Ma r g a ret T h a t c h e r, then our Se c re t a ry of
State, wanted to be briefed as to what she should do about this. We had a discussion: we
had all of us known the background over the last few years, that there was by and large
a plan (plot – whatever you like to say) that they we re going to pick off the Re s e a rc h
Councils one by one as being the easiest thing. We discussed this and had to decide then
and there; of course there was no way we could ask the views of our Councils about this.
We made the decision to ask her to say to the Cabinet, ‘All or none’, and that we would
fight the battle with all of the Re s e a rch Councils standing together rather than risk first
of all the ARC, then the NERC, which was already under attack, and we certainly had
fair warning that we [the MRC] we re going to go within about a ye a r’s time. We took
the decision then and there to say, ‘All or none’. Ma r g a ret Thatcher accepted this and
fought this at Cabinet the next day and Cabinet agreed not to decide on the Os m o n d
Re p o rt, but to allow Fred Dainton, as the Chairman of the CSP, to consult and pro d u c e
a re p o rt from his point of view. It was on the condition that there would be a final re p o rt
f o l l owing the Dainton re p o rt, from some independent person who would take all this
into account. This, of course, turned out to be Ro t h s c h i l d .1 5 2
Fred Dainton’s committee met throughout that winter. At first there were two-day
weekend meetings, at which the chief executives of the Research Councils were
151 Sir Paul Osmond Kt CB (1917–1998) joined the home Civil Service in 1939, in which he served until his
retirement in 1975. He was Deputy Secretary in the Civil Service Department at the time of the Fulton Report
on The Civil Service (1968) to 1970, moving to the Office of the Lord Chancellor from 1970 to 1972 and the
Department of Health and Social Services from 1972 until 1975.
152 The official version is related by Margaret Thatcher in her evidence on 3 May 1971 to the Select Committee
on Science and Technology. See House of Commons, Select Committee on Science and Technology. (1971) Second
Report, Session 1970–1971, Research Councils. HoC 9. London: HMSO, para. 16, page 16. 
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present. Then the rest of the committee, which didn’t include us, met to put a report
together. That went to Rothschild and then Rothschild published his report in the
same volume as that of the Dainton committee. After that, it was a case of carrying
out the strategy of all standing together. We attended each other’s council meetings
and things of this kind. When we met various government bodies in general we all
met collectively together before and spoke for the Research Councils as a whole. I
know there were some people who didn’t approve of this tactic. They thought that the
MRC was above the research council system and we would have done better to stand
on our own. I never believed for a moment that that was true, and I don’t think there
were many people who took that view. I do know that there were some. But for
obvious reasons, and this is perhaps one of the lessons about how Research Councils
work, there are moments such as that described where a chief executive has to speak
for the council on the spot without being able to do anything about it. There are
people in this room I know who were members of the Council at that time. Now, after
all these years, what do you think? Are you going to tell me that I made a terrible
mistake? If so, you may say so.
Walton: But in effect, it is right is it not, the result of the Rothschild Report, which
the Government accepted, was that major parts of the MRC’s funds were transferred
to Health Departments, but the Health Departments in most instances used those
funds to commission work already being done through the MRC. For instance, I
know that my own programme grant, which was in a clinical field, was immediately
transferred to the DHSS. 
Gray: Perhaps I could just say one or two words. I think the aftermath is something I
might comment on. I ought to finish off by saying that once the Rothschild Report
was out, a major battle still went on for another six months or so and the Research
Councils did manage to get a number of, what to me were crucial, amendments. One
of the crucial issues was what was applied research and that is when we came up with
this word ‘strategic’, because one side wanted to say that, for example, the work on
molecular biology was fundamental and the other side was wanting to say, ‘Ah, but
this is all cancer research’ or whatever it was. So we introduced the concept of strategic
research which we did not think should be transferred to the Health Department.
Walton: Now before I come to Douglas Black, may I turn to Sir Patrick Nairne. You
were at that time Permanent Secretary in the Department?
Sir Patrick Nairne:1 5 3 I became Permanent Se c re t a ry in November 1975, three ye a r s
after the Rothschild Re p o rt’s implementation began, so let me take it from there. Fi r s t ,
I ought to say that I have n’t, as they say in the law courts, been able to re f resh my
153 The Rt Hon Sir Patrick Nairne GCB MC (b. 1921) had a Civil Service career from 1947 to 1981 serving in
the Admiralty, the Ministry of Defence and the Cabinet Office. He was Permanent Secretary of the Department
of Health and Social Security from 1975 until 1981. He was Master of St Catherine’s College, Oxford, from 1981
to 1988 and Chancellor of Essex University from 1983 to 1997.
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m e m o ry, beyond managing to find a re p o rt of a Public Accounts Committee (PAC) of
1 9 7 91 5 4 when Arthur Buller and I we re together, along with Jim Gow a n s ,1 5 5 g i v i n g
evidence on how effective in relation to the DHSS the Rothschild Re p o rt had been.
When I arrived at the De p a rtment of Health and Social Security in 1975 it was quickly
made clear to me that we we re in the process of exploring whether there could be better
ways of implementing Ro t h s c h i l d’s recommendations. I was led to believe at the time
that the MRC had always advised against it, while the Government had taken the line
that the MRC was bound to be opposed, and it had gone ahead with implementation.
I think I am right in saying that the total funds we re of the order of at least £2–3 million. 
The Department initially undertook a review of the whole of the MRC programme
and identified those features of it which were of special priority to the NHS. It very
soon became evident that this was a very burdensome procedure indeed, because the
next stage was an attempt on the Department’s part – and I found this going on when
I arrived – to relate the amount of money that had been transferred to us to different
carefully identified parts of the MRC programme, a rather artificial process. I think I
should add that there was a little bit of direct commissioning of research as well. I am
reminded, from looking at the Public Accounts Committee re p o rt, that we
commissioned the MRC on ultra-clean air, on influenza vaccines and on a study
relating to drugs for whooping cough. But this commissioned work was very small
compared with the main bulk of the transferred funds. In this situation, first Sir John
Gray, and then Sir James Gowans, when he arrived in 1977, made clear that we ought
to see whether we could together work out quickly a less burdensome arrangement.
Sir James Gowans also made clear that he wanted the transferred money back and that
he was very determined to get it. The formulation of a less burdensome arrangement
was much assisted by an exercise which I recall was initiated by Douglas Black – he
can probably recall, and speak about it, in a minute – where he and one of the
Department’s economists worked out a scheme they entitled ‘the burden of disease’.156
This was based on giving a degree of priority to diseases in terms of morbidity,
sickness, health benefit, and any other relevant factors at that time. 
154 House of Commons, Public Accounts Committee. (1979) First Report, Session 1979–80, The Ministry of
Agriculture, Fisheries and Food, Department of Industry, Scottish Economic Planning Department, Welsh Office,
Department of Education and Science, Medical Research Council, Scottish Home and Health Department, Agricultural
Research Council, Department of Agriculture and Fisheries for Scotland. HoC173. London: HMSO. The Committee
particularly looked at the research and development work commissioned from Research Councils as a result of the
1971 Rothschild Report and the 1972 White Paper (Cmnd 5046). Gowans, Nairne and Buller gave their evidence
in March 1979. The PAC noted that the DHSS originally took £10 million or 25 per cent of the MRC budget in
1975–1976 for direct commissioning, declining slightly over the five-year period to 21 per cent, and concluded
that due to the MRC’s method of controlling research, there was little point in the Government continuing the
commissioning arrangements. The new Conservative Government agreed and the funds were returned to the
MRC from 1 April 1981. See Anonymous. (1980) Notes and News: Goodbye Lord Rothschild. Lancet ii: 986.
Buller A, Gowans J L. (1981) Medical research and the funding of the MRC. British Medical Journal 282: 820.
155 See note 87. 
156 Black D A K, Pole J D. (1975) Priorities in biomedical research: Indices of burden. British Journal of Preventive
and Social Medicine 29: 222–227. Sir Patrick Nairne described the value to the DHSS of the resulting index or
rating of the burden of disease in evaluation of the distribution of funds being spent on different parts of the MRC
programme. See note 154, para. 1295, 87.
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The outcome of this work enabled the Department to produce broad annual
statements about research priorities affecting the NHS, as seen by the Department.
On the basis of those broad statements we had meetings – not more than one or two
a year – with the Secretary of the MRC and his colleagues and that proved to be a
valuable interaction. I should emphasize that it became evident that, without the
Rothschild Report (for all its defects), I don’t believe that the kind of valuable
interrelationship with the MRC that we gradually developed would have emerged.
Douglas Black can speak, and if necessary correct me, about this. When he retired
from the DHSS, Arthur Buller, who will speak himself in a minute, became Chief
Scientist. He then became, or perhaps was already, a member of all the MRC Boards
and, I think, of the MRC itself. So, to sum up, the arrangements that we developed
together with Sir James Gowans, through refining Departmental statements as a basis
for interactive discussion each year, led to a better understanding between ourselves
and the MRC, which was reinforced by the way in which the Chief Scientist had a
foot in both camps, the MRC camp and the Departmental camp.157
But Sir James Gowans hadn’t yet got his money back, and it then turned out that the
C o m p t roller and Auditor General decided to examine what had actually been
happening to the transferred funds in the MRC–DHSS field, and also in the Mi n i s t ry
of Agriculture, Fisheries and Food (MAFF) and the Agricultural Re s e a rch Council
( A RC) field. This led to his re p o rt to the Public Accounts Committee and to the
De p a rtment and MRC being summoned to an exacting session of the Public Ac c o u n t s
Committee in Ma rch 1979. It is that PAC re p o rt I have been able to read again. Si r
James Gowans opened up with a brilliant statement of the MRC ’s position and policy,
and there was a good deal of ‘Yes, Sir Ja m e s’ and ‘No, Sir Ja m e s’ from the Committee
which was quickly and deeply impressed by all he had to tell them about the way the
M RC saw matters. The Committee then turned to the Permanent Se c retaries of the
t h ree Health De p a rtments and the tone became, ‘Look here, Sir Pa t r i c k’ about the
issues being discussed. But in general the spirit, as Arthur Buller will confirm, became
p retty friendly fairly soon once we had explained the interre a c t i ve arrangements that we
had developed. T h e re is more that Professor Buller may wish to add to this; I would
only wish to add that the Comptroller and Auditor General then re v i ewed all the
evidence and pre p a red a re p o rt for the Public Accounts Committee. In this he said in
e f f e c t: ‘ Is n’t all this commissioning process – that is, the relating of the transferred MRC
money to certain De p a rtmental priorities – a ve ry artificial, burdensome and
b u reaucratic process? Do we really need it?’ In due course there was even stro n g e r
p re s s u re that the money should be returned to the MRC, and some of it was re t u r n e d .
But, as I think Arthur Buller can fill out, because he knows the papers better than me,
some of it was kept by the De p a rtment. Then in 1981 I re t i red from the De p a rt m e n t .
157 The Advisory Board for the Research Councils identified problems with the partnership of the MRC and the
Health Departments and described the change in responsibility of the Chief Scientist after August 1978 as from
one who ‘solely acted in an advisory capacity in respect of the Departments’ projects’ to one who had ‘executive
responsibility for biomedical, health, personal social services and social security research while retaining an advisory
role in relation to other areas of the Department’s research.’ Department of Education and Science. (1979) Third
Report of the Advisory Board for the Research Councils 1976–1978. Cmnd 7467. London: HMSO, para. 33, 10. 
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Walton: Douglas Black, you were Chief Scientist from 1973 to 1977, so it would be
fascinating to hear your experiences of that period.
Black: Yes, I come into this gap between 1972 and 1977. Could I say one or two
rather separate things? First of all, I am always charmed to be able to pay a tribute to
Margaret Thatcher, because as suggested she was extremely supportive of the anti-
Rothschild position and was quite distressed when things went (as I think John [Gray]
and I would agree) the wrong way round. 
Then the next thing is that Pat Nairne mentioned ultra-clean air. This wasn’t actually an
early example of environmentalism, it was ultra-clean air in surgical theatres. Then I have
often, I am sure, been subconsciously out of my depth, but the occasion when this ro s e
to the threshold and above the threshold of consciousness, was of course during the
period when I was in the De p a rtment of Health, because I was there to implement a
p rocess in which I had no fundamental belief. I mean Brian Wi n d e yer and I have had a
joint letter to The Ti m e s,158 which was as unavailing as eve rything else at the time in try i n g
to defeat Rothschild. Then I was put into the position of implementing Rothschild. T h e
last defence of the confirmed villain is to say, ‘I have tried hard’. But I did try hard and I
think we we re ve ry lucky in that because of the commissioning process, a bure a u c r a t i c
p rocess of the utmost complexity was built up in which we had committees which we re
far too large for their purpose. This was partly because of that troublesome country
Scotland, because eve ry English member of the UK committee had to be matched with
someone from Scotland. It didn’t quite extend to No rthern Ireland, perhaps for good
reasons! Anyway and there was the appalling commissioning process which meant that
poor John [Gray] had to do triple accountancy on eve ry transaction which invo l ved the
De p a rtment. It had to be divided into MRC proper expenditure, commission-fund
e x p e n d i t u re, and then within that what was supposed to be of departmental interest, etc.
I think that I re c e i ved the ultimate accolade from that honest and ve ry influential pare n t
of evidence-based medicine, Archie Cochrane, because he’s on re c o rd as saying that in
that post as Chief Scientist, I was hopelessly miscast. 1 5 9
Wa l t o n : Well, that may have been his view, but I cannot help but recall ve ry well at the
time that Ni xon had decided he was going to throw a lot of money at cancer in the Un i t e d
States to cure it within five years, I remember your comment, Douglas, in your Ro c k
Carling lecture when you said that ‘lavish finance is impotent in the face of unripe time’ ;1 6 0
158 Professor Douglas Black and Professor Sir Brian Windeyer. (1972) Letters to the Editor: The division of
governmental responsibility for research. The Times (11 January 1972), 13. Letter written as past and present
Chairman of the MRC Clinical Research Board.
159 Cochrane A L with Blythe M. (1989) One Man’s Medicine: An autobiography of Professor Archie Cochrane.
London: British Medical Journal, 245. See also Maynard A, Chalmers I. (eds) (1997) Non-random Reflections on
Health Services Research: On the 25th anniversary of Archie Cochrane’s Effectiveness and Efficiency. London: British
Medical Journal Publishing Group.
160 Black D A K. (1984) An Anthology of False Antitheses. The Rock Carling Fellowship 1984. London: Nuffield
Provincial Hospitals Trust, 12. See also Department of Health and Social Security. (1982) The Support of Health
and Personal Social Services Research. London: DHSS.
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161 Professor Sir Sam Edwards Kt FRS (b. 1928) was Professor of Theoretical Physics at the University of
Manchester from 1963 to 1972, the John Humphrey Plummer Professor of Physics from 1972 to 1984, and the
Cavendish Professor of Physics from 1984 to 1995 at the University of Cambridge. He was Chairman of the
Science Research Council (later the Science and Engineering Research Council) from 1973 to 1977.
162 For Dainton’s biographical details, see note 125.
a n d that is a quote that I have used on a number of occasions since. Thank you for
sharing that perception with us. Before I come to Arthur Buller who succeeded you
in 1978, which was the year that I came off Council, just as the whole impetus for the
return of the transferred funds was gaining pace in the scientific community, I wonder
if any members of the audience who were involved in the work of the Council at that
time would like to share their views upon what they saw as the effects of the
Rothschild mechanism?
Booth: I was the successor to Stan Peart on the Advisory Board for the Research
Councils (ABRC) and this body, after Rothschild, had to divide up the money
between the different Research Councils. This happened at one meeting at which all
officials were banished leaving only the independent members, of which I was one,
who had to argue the case for whatever subject they were interested in. I remember it
was extremely chancy as to what the MRC got in terms of its overall budget. I
remember one time when a presentation was made by the MRC, and I forget which
board it was, but at the discussion afterwards when the MRC’s budget was being
discussed, a very important man indeed, now no longer with us, Fred Dainton, got
up, I remember, and said he’d listened to the MRC and he couldn’t think that it really
mattered whether the budget for the MRC went up 5 per cent or down 5 per cent and
he reckoned it should go down by 5 per cent, and that was the sort of argument that
went on in that body. I found it absolutely, paralytically horrifying and I remember
discussing it with John Gray when I joined the ABRC and I said, ‘I presume it’s all
worked out by officials beforehand’ and he said, ‘Not a bit of it, you are on your own,
boy’. And, by George, you were at that body. And I can remember on that occasion
we finished up with +0.8 per cent or something like that at the end of the discussion.
But I didn’t think that it was a very satisfactory way of discussing how you should
allocate resources with people like Sam Edwards,161 representing the Science and
Engineering Research Council, with tears streaming down his face, I mean literally,
making an argument for telescopes in Hawaii or something like that, or is it the
Canary Islands? (From the floor – Both.)
Wa l t o n : I am mildly surprised that Fred Dainton took that view, because of course he
subsequently became Chairman of the Postgraduate Medical School at Ha m m e r s m i t h ,
and was active in the House of Lords until he sadly died a few months ago.1 6 2 He was
immensely support i ve of medicine and of the Medical Re s e a rch Council. Now, any
other views about the effects of the Rothschild Re p o rt upon the support of re s e a rc h ?
Lachmann: From my worm’s eye view of this matter, I just wish to pay a tribute to Sir
Douglas Black. At the relevant period I was at the Hammersmith and had one of the
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Medical Research Council research groups which have already been mentioned.163
This covered a fairly broad spectrum of immunology, but a relatively small proportion
of it was devoted to work on the measles virus and the various diseases that it caused.
I was immensely impressed when I saw our accounts one year to notice that Douglas
had been able to attribute to the Department of Health under the Rothschild
arrangements the whole of the group’s funding in connection with the work on
measles, and I thought, ‘Here is a man who can make even the worst system work’.
Walton: Just for the record and to get the situation straight. Douglas, as Chief
Scientist, you were an observer on Council, were you not? Were you an observer on
the Boards as well?
Black: There’s taxonomy trouble in that there was great dispute about whether one
should be an observer (or a member). I was actually a member of all those things.
Walton: You were? Of Council as well?
Black: Everything. No committee existed without my participation. [Laughter]
Walton: But there was also, John Gray, an interesting arrangement, if you recall,
where you took members of certain boards and invited them to be the spies upon
other boards. I was actually nominated from the Neuroscience Board to be a spy on
the Systems Board. It was an interesting experience.
Gray: I would like to make one comment about the application. Everything we have
been talking about here quite properly has been concerned with the transfer of funds
from the MRC to the Department of Health. We also transferred a small amount of
funds to the Health and Safety Executive, and that was an absolute disaster. As far as
I know, the sum was small, and whether we had actually given up trying to get any of
this money back when I retired, or whether it happened afterwards, I really can’t
remember, but that was a complete disaster.164
Peter Williams: I just wanted to ask Douglas if today he feels he might be accused of
‘conflict of interests’?
Black: I am reminded of something that happened at Sir Philip Rogers’s retirement
party. He said that in the palmy days of the Civil Service, you were allowed to send
back a letter which said, ‘I am directed by the Secretary of State to inform you that
your question is not among those selected for a reply’. [Laughter]
163 For Black’s biographical details, see note 6.
164 The Re v i ew noted that the programme undertaken by the MRC for the De p a rtment of Em p l oyment (thre e -
q u a rters of the original funds for Em p l oyment was later transferred to the Health and Safety Exe c u t i ve) was ‘t o o
academic in orientation and narrow in scope to contribute substantially to the main policy interests although it was
clearly focused on employment issues of general concern to the De p a rt m e n t .’ The Lord Privy Seal. (1979) Review of
the Fra m e w o rk for Gove rnment Re s e a rch and De velopment (Cmnd 5046). Cmnd 7499. London: HMSO, 44.
165 Professor Arthur Buller FRCP (b. 1923) was Professor of Physiology at the University of Bristol from 1965 to
1982, later Emeritus, and Dean of the Faculty of Medicine from 1976 to 1978. He was seconded to the DHSS as
Chief Scientist from 1978 to 1981. He was Chairman of the MRC Neurosciences Board from 1976 to 1978 and
of the DHSS Working Party on Clinical Accountability, Service Planning and Evaluation from 1981 to 1986.
166 See note 156. From 1978–1979 the simplified arrangements involved the Health Departments providing the
MRC with an annual statement of health problems and priorities analysed by the burden of diseases under 27
broad headings. 
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Walton: On that note, I think we should go on to hear Arthur Buller talking about
his experiences and the period during which it became apparent that the right thing
to do was to re-transfer the funds. However, Arthur, I would like to just clarify one
point. I think that Rothschild did lead to a few important developments in the MRC
relating to the support of health services research and operational research in the
NHS; if you would like to comment upon how that was seen from the Health
Department’s view, it would be helpful.
Professor Arthur Buller:165 The first thing I should like to recall is that Douglas Black
was elected President of the Royal College of Physicians on 4 April 1977. I attended
the College that day to take part in the election, and I voted for Douglas. Had I
known at that time of  the implications for myself of Douglas’s election, I might have
cast my vote differently!
Before David Ennals appointed me Chief Scientist, Pat Nairne invited me out to
lunch. He first wrong-footed me by inviting me to choose the wine – something I
declined to do – and then explained to me something of the implications of the
Rothschild requirements at the DHSS from the civil servant’s point of view.
Before attempting to convey my interpretation of Pat Nairne’s observations it is
pertinent to remind you of some relevant facts. Douglas Black was Chief Scientist at
the DHSS from 1973 to 1977. Whilst I am a great admirer of Douglas I think it was
stretching a point to say that he implemented Rothschild. I think he ‘avoided’
Rothschild in a masterly way, but it did make for some difficulties. Pat Nairne was
appointed Permanent Secretary at the DHSS in 1975. At that time Henry Yellowlees
was Chief Medical Officer and Douglas Black, Chief Scientist. Pat [Nairne] had spent
an appreciable part of his civil service career in the Ministry of Defence, a government
department with a large and competent scientific component.
Over lunch, Pat explained to a naive Arthur Buller that as Permanent Secretary he was
the Accounting Officer for the funds the department spent with the MRC on
commissioned research. In line with the concordat negotiated by John Gray this
money had to be spent on biomedical topics. As Sir Patrick has already said, even after
the introduction in 1977 of the revised procedure for commissioning based on Black
and Pole’s ‘Burden of disease’,166 the laborious exercise was ‘...a rather artificial
process’. Rightly or wrongly I interpreted our conversation over lunch as indicating
some unease on Pat’s part as Accounting Officer and a wish to explore alternative
models of the Department’s involvement in research, especially with the MRC.
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Certainly Pat was very conscious of Jim Gowans’s wish to see the Rothschild money
returned to the MRC (Gowans became Secretary to the MRC in 1977).
My first year in the Department, some of which was part time, was very much spent
in ‘learning the ropes’ and assuming an administrative role that Douglas had declined
to accept. It was soon apparent that if the department was truly to attempt to
implement Rothschild there was a need for a considerable increase in scientific
manpower. If this proved to be impossible a closer, but less formal, association with
the Research Councils, SSRC as well as MRC, was in my view the only alternative.
During 1978 Sir Kenneth Berrill167 and John Ashworth168 of the Cabinet Office were
conducting a review of the Rothschild arrangements. The report, published in 1979,
mentioned the shortage of research managers and the lack of positive research
planning at the DHSS.169
To my mind the die was cast on 3 May 1979, when the Conserva t i ves won the
election and moved into government. It was immediately apparent that financial
re t renchment was the order of the day and the possibility of building up a fully
competent Chief Scientist office in the DHSS was, at that time, a non-start e r.
Indeed, reductions in staffing we re called for. I believe that it was at this time that
Sir Patrick became fully convinced that the only way forw a rd was to attempt to
negotiate a new concordat with the MRC and return all, or at least most, of the
t r a n s f e r red funds.
Pat Nairne has already referred to our meeting before the Public Accounts Committee
with Jim Gowans. I agree that Jim spoke in a typically forceful and convincing manner
in support of the return of the Rothschild funds, but I think that I should add that
Pat played a very low-key game! I have heard Patrick Nairne in other places, and at
other times debate much more astutely on equally weak cases. I believe that he was
already convinced that, for the Department, the way forward was to obtain the best
possible deal with the MRC for the return of the transferred funds.
Apropos Rothschild, the remainder of my time at the Department was spent in detailed
negotiations with Jim Gowans concerning the new concordat. The new concordat was
agreed by the MRC in October 1980 and implemented in 1981. The major part of
the transferred funds, but not all, was returned to the MRC, the Department retaining
167 Sir Kenneth Berrill GBE KCB (b. 1920), economist, was Head of the Central Policy Review Staff at the Cabinet
Office from 1974 to 1980, having served as Special Adviser on public expenditure to the Treasury from 1967 to
1969, Chairman of the University Grants Committee from 1969 to 1973 and Head of the Government Economic
Service and Chief Economic Adviser to the Treasury from 1973 to 1974. He was a member of the Council for
Scientific Policy from 1969 to 1972, the Advisory Board for Research Councils from 1972 to 1977, and the
Advisory Council for Applied Research and Development from 1977 to 1980.
168 Professor John Ashworth FIBiol (b. 1938) was seconded to the Cabinet Office from a chair of biology at the
University of Essex from 1974 to 1979 where he was Chief Scientist to the Central Policy Review Staff from 1976
to 1981. He was Vice-Chancellor of the University of Salford from 1981 to 1990 and Director of the London
School of Economics from 1990 to 1996. He has been Chairman of the British Library Board since 1996.
169 See note 164, 7. 
170 See note 154.
171 The 1979 Royal Commission on the National Health Service suggested a health services research board. See
‘Concordat with the Health Department’, Medical Research Council Annual Report 1980–1981, 4–5; ‘Co-operation
with the Health Departments’, Annual Report 1981–1982, 6–7, for details of implementation.
172 Sir Henry Yellowlees KCB FRCS (b. 1919) was Chief Medical Officer at the Department of Health and Social
Security, the Department of Education and Science and the Home Office from 1973 to 1983. He had been at the
North West Metropolitan Regional Hospital Board from 1959, when seconded to the Ministry of Health as
Principal Medical Officer in 1963, when appointed Deputy Chief Medical Officer to Sir George Godber in 1967,
and second Chief Medical Officer in 1972 until Godber’s retirement in 1973. 
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some money for possible commissioning as well as its own Health and Personal Social
Services research budget.170
That, in very brief summary, is the story as I remember it. I think it approximates to
what actually took place.
Wa l t o n : Thank you. It led, did it not, to the development of the Health Se rvices Board ?1 7 1
Buller: That’s right. That was part of the deal with Jim [Gowans]. However, it seemed
to me that, de facto, the Health Services Board turned out to be a rather poor relative
of the three main boards.
Wa l t o n : He n ry Ye l l ow l e e s ,1 7 2 by the way, has sent his apologies, he couldn’t be with us
t o d a y. Was it the case that he was unhappy about the return of those transferred funds?
Buller: I think Sir Patrick would have been as conscious as I was that the Department
did not want to see the money go back to the MRC. Perhaps Henry Yellowlees was
the primary spokesman for this view. He believed that retaining direct control over the
money gave the Department more clout. My problem was that I could not see how
that clout could usefully be employed. In the end, as I have said, the Department did
retain a small part of the transferred funds for future commissioning.
Nairne: If I could very briefly add a point, stimulated by Arthur’s account, which I
think is broadly accurate. I don’t think that, as Permanent Secretary and Accounting
Officer, I was unduly fussed about the accounting aspect, at least not to begin with.
The recommendations of the Rothschild Report, as you yourself have said, had been
accepted by the Cabinet and they had to be given a fair run; and it had been agreed
from the start that they should be reviewed after several years. In general, as you
yourself will know, it is rather difficult to get ministers closely interested in research.
It is long term, it is uncertain, and there are very few votes, if any, in it. But actually
we did have a Minister in Dr David Owen (now Lord Owen), who did take quite a
close interest, and he was very much in favour of banging that rather well-known
drum to the effect that millions of working hours are lost through, for example, back
pain and the MRC won’t give any research priority to back pain. That was certainly a
cry I heard from Dr Owen; and it is a fairly frequent example of the way the
Department, including Ministers, does not always understand the way research has to
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be conducted. So when the Public Accounts Committee review had been completed,
it had to go back to Ministers. That reflected the somewhat stately and bureaucratic
process that you are well aware of yourself and many people in this room are aware
of, and which had then to take place. But, in my judgement, in the end there were
the constructive outcomes affecting the MRC and the NHS that you were seeking to
emphasize yourself. Could I just add on a more flippant note? Why did I ask Professor
Arthur Buller to choose the wine? It was because we had been reassured to find, on
his appointment as Chief Scientist, that the word ‘claret’ was included among his
recreations in Who’s Who.
Walton: Tony Dornhorst, you and I served together on the MRC, just before this
period. Do you have any comments that you wish to make upon the effects of the
Rothschild changes on clinical research?
Professor Tony Dornhorst:173 The effect was nil. It’s as simple as that. When it was
introduced there was a great fluttering in the dovecotes. As Sheila [Howarth] can
confirm, we thought all sorts of nasty things would happen. In the event of course,
as regards the day-to-day work and so on, nothing happened. The Department of
Employment174 did in fact succeed in commissioning a project and it was a very good
idea. They wanted a portable device which could be used in the field to diagnose
disease of the small airways. An excellent idea. As you will almost certainly know, we
could still use such a device, but it doesn’t exist. So that wasn’t a great success,
although they showed willing. Until we both left, the Department of Health hadn’t
produced any commissions at all, so the whole thing was really a non-event. 
Walton: Thank you. Douglas, I think one of your concerns, am I right in saying, was
that whereas the MRC from the date of its establishment had created a substantial,
effective, and skilled infrastructure of scientists and others who were accustomed to
looking at research, you found it difficult to identify a similar infrastructure in the
Department which had not primarily been concerned with developing research
programmes? Was that a factor?
B l a c k : Yes, there was a lack of appropriate re s e a rch-oriented infrastru c t u re within the
DHSS, as compared with the MRC; not surprisingly, since the MRC was able to
concentrate on the administration of re s e a rch, whereas the De p a rtment had many other
responsibilities. Also, in the units supported by the DHSS, there was a shortage of ‘m i d d l e
m a n a g e m e n t’, leaving the head of the unit supported only by rotating junior staff, like a
‘naked pro f e s s o r’. Sh o rt-term contracts did not give encouraging tenure to senior work e r s ;
and the alternative of becoming established civil servants was apparently unattractive .
173 Professor Tony Dornhorst FRCP (b. 1915), was Professor of Medicine at St George’s Hospital Medical School,
London, from 1959 until his retirement in 1980 and a member of the MRC from 1973 to 1977.
174 See note 164.
175 Professor Donald Munro wrote: ‘The Trent Regional Health Authority was not alone in providing funds for
audit work when regular data on performance first began to be sought from hospitals. It was an obstacle to
persuading such authorities to fund any other research work on more fundamental aspects of clinical research and
two committees – one for “audit” and one for research frequently passed applications for funding to one, over to
the other – as they were both stretched financially.’ Letter to Mrs Lois Reynolds, 9 April 2000.
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Walton: In the recent past, of course, there has been a significant change, with the
development of the Department’s R&D structure, which of course is a new scenario
entirely, but is outside the decades with which we are dealing. Are there any other
comments then about this whole issue of Rothschild and the developments which
followed? If not, can I ask what people began to perceive as the decade, 1970–1980,
moved on, of the effects that began to emerge of the University Grants Committee
cuts on the universities. Certainly in the last few years that I was Dean (1971–1981)
in Newcastle, we began to find that those cuts were making it extremely difficult to
provide the infrastructure and the support that was needed by research workers, even
those who were capable of bringing in very substantial research grants. Would anyone
wish to comment?
Buller: Could I say a word there, because I returned to my university department from
the old DHSS in 1981, which was just when those cuts were coming in, and it took
me a full fortnight to realize why my ex-colleagues were looking at me in a strange
way. I then learned that the department had been asked to find two redundancies, and
in their eyes there was the message, ‘Arthur, we have done without you for three years
and therefore your absence won’t matter’. So the effect on me was early retirement.
Munro: I think I would like to endorse the comment that you made yourself, Mr
Chairman, namely that one saw, first of all, a disappearance of the funds which used
to be made available within departments to start people off, to show them that they
had it in them to do independent work. And secondly, there was an increasing
tendency for the MRC report on research grants to come back with ‘high grades but
not funded’. I remember Lord Dainton used to come round frequently and ask how
often this had happened. I don’t think anything happened as a result of his enquiries,
but clearly he was aware of the fact that the constraints on funds were certainly
limiting lots of promising projects. There was another factor at the time. When we
were all asked to audit our clinical activities, there were funds set aside by the Trent
region to fund audit work.175 At one stage they put as much as £300 000 aside to fund
this work, which was in fact only 0.03 per cent of their annual budget. It was a very
large region. And there was a great tendency for the board dealing with those audit
requests to say, ‘This isn’t audit, this is research’, and for the local research committees
to say the same thing in the opposite way.
Hoffenberg: I was head of a large department of medicine for most of that decade.
Certainly we felt the impact of funding cuts, but on the whole we managed to find a
way through the system and get the money we needed, often through alternative new
sources. The big problem was the effect it had on recruitment. Young people sensed
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that academic medicine would not be well funded and would not provide the security
of the NHS and many bright prospects were lost. 
Walton: Ian McDonald, did you wish to come in on this problem?
Professor Ian McDonald:176 Yes, really to reiterate what Bill Hoffenberg has said. This
was a period in which I was very actively involved in building up a group of people,
and I have to say that in neurological research it was not as difficult as I understand it
was in some other disciplines, but it became quite striking by the end of the 1970s,
when it was becoming difficult to get manifestly very able people, committed to a
research career.
Gordon: When the Trust was setting up a committee last year to look at the Trust’s
Clinical Facilities scheme, because all the big players in the UK were applicants, the
committee came almost entirely from the United States. Stan Peart earlier on alluded
to his membership of it as an elder statesman. One of the people we recruited was
John Marshall,177 who is now at the University of Virginia, and he had actually been
in Bill Hoffenberg’s department at the time he has just described. Even though John
Marshall was well-funded as a Wellcome Trust Senior Research Fellow, he actually was
driven away by the poor morale. He commented a number of times as we did site
visits to several universities last year, at the way in which it had taken a very long time
for morale to come back and for people to start to see the possibilities. So a downward
turn at that time had very long-term effects to an outside observer.
Peter W i l l i a m s : In 1979 the Wellcome Trust created Senior Lectureships and, a ye a r
or two later, Lectureships. This was a response to the UGC cuts. T h e re we re some
300 applicants for Senior Lectureships and about 35 we re appointed. So there
would have been 270 that didn’t get them, but who clearly thought that their jobs
we re in jeopard y, that’s why they we re applying. The fact was though that when it
came to the Trust looking at these Senior Lectureships, although they we re Se n i o r
L e c t u reships, I think the selection process was almost identical to the Se n i o r
Clinical Fe l l ows. That was the type of assessment that we used. And the outcome
was that out of these 35 appointees, about half of those we re clinical, so some 15 or
so people we re rescued for clinical re s e a rch by this Trust scheme. The Trust thought
it had got all that it was desirable to support, especially in re s e a rch terms. It did not,
in my view, limit the number because it didn’t have the money, it was ve ry flush at
that time.
176 Professor Ian McDonald FRCP F MedSci (b. 1933) was Professor of Clinical Neurology at the Institute of
Neurology, London, from 1974 to 1998. He has been Harveian Librarian at the Royal College of Physicians of
London since 1997.
177 Professor John C Marshall held a Wellcome Trust Senior Research Fellowship in Clinical Science at the
Universities of Birmingham and Michigan from 1974 to 1979. He was appointed Professor of Internal Medicine
at the University of Michigan in 1979, and Chief of the Division of Endocrinology and Metabolism from 1987
to 1990. In 1991 be became Arthur and Margaret Ebbert Professor of Medical Science at the University of
Virginia, and is now Director of their Center for Research in Reproduction.
178 Of 84 Wellcome Trust Medical Graduate Fellows after 1985, seven moved directly to senior lectureships (one
later to a chair); 20 to lectureships (7 later moved on to senior lectureships); two to senior fellowships, 15 to
become registrars (of which one to a senior lectureship and four to senior registrar) and 24 to senior registrar (one
later went on to a senior fellowship and four became consultants). See Gordon D. (1994) Building bridges:
Research opportunities for clinicians. TRP3: Research and Funding News from the Wellcome Trust 1: 10–11.
1 7 9 Dr J M New s o m - Davis was awarded the first MRC Clinical Re s e a rch Professorship as MRC Clinical Re s e a rc h
Professor of Ne u rology by the Un i versity of London at the Royal Free Hospital and the Institute of Ne u ro l o g y. Se n i o r
Aw a rd Schemes began in 1978–1979 to support established re s e a rch workers, who we re ‘expected to devote their
whole working time to re s e a rch in medical schools, undertaking such patient care as is necessary for this re s e a rch but
not taking part in routine university teaching or administration ...to re t i rement age.’ House of Commons. (1980)
Medical Re s e a rch Council Annual Re p o rt April 1978 – Ma rch 1979. HoC219. London: HMSO, 69.
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Wa l t o n : Could I ask whether the [Wellcome] Trust did or has done any kind of follow -
up of the subsequent career patterns of individuals who held such appointments? T h e
reason I ask that is because in my department I had seven Wellcome Senior Fe l l ow s h i p s
in Clinical Science at different times; of those, two have subsequently become
p rofessors, one in the States and one in Australia, while others have become consultants
in the NHS, with an interest in re s e a rch. Many have been so driven by the major
b u rden of clinical responsibility that they have done ve ry little re s e a rch since they we re
g i ven those appointments. One of them has. So I think that about a 50 per cent
outcome is not too bad. But what has happened to the Wellcome Senior Lecture r s ?
Williams: David [Gordon] is the man to ask.
G o rd o n : We have looked at where people go and what they do. W h e re they go is re l a t i ve l y
easy to find; certainly with medical people you can find out where they have gone thro u g h
the Medical Dire c t o ry and so on. Scientists still publish and leave footprints all over the
scientific literature. It is easier to find the job that people are in, and it’s a much higher
success rate overall than 50 per cent.1 7 8 Former Senior Fe l l ows and Wellcome Se n i o r
L e c t u rers end up in ve ry good and ve ry worthwhile and important appointments. What we
h a ve n’t done in the same detail, but we are starting to do, is to look at what they actually
do, what they are publishing. It is all ve ry well to be professor of something, somew h e re, but
if you are not actually publishing anything ve ry much or have n’t encouraged other people,
then it may not have been worthwhile. I think it does lead me to comment that if you are
really going to do something, if you are responsible for clinical re s e a rch, to set up a unit is
fine, to build buildings is fine, but in the end if you have n’t got the people, then it will get
n ow h e re. Despite all the pushing and shoving and where the money is shifted to and fro m ,
if there hasn’t actually been someone in there saying, ‘Who are we going to identify to make
s u re clinical re s e a rch will go forw a rd in the future?’, then it is just not going to happen.
Booth: I think this question of people is absolutely crucial and the fundamental
problem here is whether you can identify people in the clinical field who are genuinely
interested in a research career. I can only say from my experience with the MRC that
that has proved extremely difficult to identify. The MRC in this period set up a new
scheme in which it wanted to identify brilliant young clinical scientists who could be
given MRC Professorships within the universities,179 and this was set up in, I think,
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about 1978 or so – and I was a member of several of those committees. In all that time,
and certainly in the decade that followed, I think we only identified four thro u g h o u t
the country, one of whom has taken on a university chair since then, another of whom
I notice is candidate for the post of Chief Medical Of f i c e r, which was hardly what we
had in mind, I may say, when we set up the professorship for the MRC. But it has
p roved in Britain extraordinarily difficult to find people who want to give up that
happy amalgam, if you like – George W h i p p l e’s triple chair,1 8 0 w h e re clinical work ,
re s e a rch, and teaching are combined – and the number of people who want solely to
do re s e a rch, as opposed to doing teaching and clinical work, is re m a rkably few.
Dickinson: I think potential researchers who are hovering between an academic career
and one in the National Health Service need some reassurance about the possibilities
of moving in both directions. Just after I was appointed to Bart’s, I had a long car
journey with John Lennard-Jones, who was subsequently appointed to the London
Hospital and became Professor of Gastroenterology. He told me of his experiences
when he became an NHS Consultant at UCH. He had been a protégé of the late Max
Rosenheim’s and assumed that when he was appointed to UCH, Max would welcome
him with open arms and give him laboratory facilities to continue his
gastroenterological research. No such thing happened. As soon as he was appointed,
he went to Max asking for laboratory accommodation and Max said, ‘You are an NHS
Consultant, you are nothing to do with the medical unit, you fight your own battles’.
The first thing I did when I got to Bart’s was as far as possible to dissolve the medical
unit completely and make no distinction whatsoever between the NHS Consultants
in any part of the medical school and the hospital and those on the medical unit. The
academic units were intended to fertilize research within medical schools. They
weren’t meant to be little empires on their own. It’s quite extraordinary that there was
one of those operating at UCH, where the first Rockefeller Professors were appointed.
Howarth: I think that we should remember that not only were the UGC funds being
cut back, but that in the middle of the 1970s there were cutbacks in real terms in the
MRC budget, and each of the boards was instructed by Council to set up what were
known as ‘hatchet committees’. Tony Dornhorst will no doubt recollect, as a board
chairman, that he and I spent a whole day going through a printout of all the work
which was supported by one of the boards, trying to identify work which might be
axed come the day. But it also created a situation which caused a certain amount of
anxiety I think in university circles, where of course the long-term commitments to
MRC units, institutes, and personnel had to be continued, so that, relatively, the
university portion of the MRC budget was liable to be diminished in order to
maintain the MRC’s own research effort.
180 Professor George Whipple (1878–1976) was Professor of Pathology at the Un i versity of Rochester School of
Medicine and De n t i s t ry from 1921 to 1955, and shared the Nobel Pr i ze in Physiology or Medicine in 1934 with
George Richards Minot and William Pa r ry Murphy for his work on studies of the live r, the bile pigments, the
formation and reconstitution of haemoglobin and the metabolism of iron. See Corner G W. (1963) George Hoy t
Whipple and his Friends: The life-story of a Nobel Pr i ze Pathologist. Philadelphia, PA: J B Lippincott Company, 155–176.
181 See note 140, 214–215.
182 Department of Health. (1994) Supporting Research and Development in the NHS: A report to the Minister for
Health by a Research and Development Task Force chaired by Professor Anthony Culyer. London: HMSO. The report
was accompanied by Press Release 94/406, 14 September 1994.
Clinical Research in Britain 1950–1980
64
Gray: One of the real problems behind all this was the lack of career structure,
security. This goes back a long time. You will remember when I was Secretary and you
[Walton] were on the Council, we had great discussions about career structures and
we produced a scheme to try and get some more career posts into the universities
instead of short-term grants. I went and visited every vice-chancellor and tried to sell
this project. In the end the whole thing flopped. The universities suspected it was
going to cost them money.
Walton: Not only that. My Vice-Chancellor at that particular time, the late, lamented
Henry Miller, said that this was a mechanism for the MRC off-loading some of its
clapped-out scientists on to the universities. And that was the attitude of several 
Vice-Chancellors at that time.
Gray:That was what we found, despite what I thought were our very good intentions.
Walton: Quite. I remember it well. Well now, I think we ought to bring the meeting
to a close.
Booth: If you are going to bring the meeting to a close, can I just give you a statistic,
in the presence of the Professor of Medical History at Johns Hopkins Hospital,
Professor Gert Brieger? I analysed the Nobel Prizes for this century and it’s interesting
that the United States, where clinical research has had a much more favourable wind
within the universities, and within that very independent scene that is America, they
have achieved something in excess of ten Nobel Laureates amongst those who are
hands-on clinicians who actually walk wards. The number in Britain, to the surprise
of many people who discussed it with me, is in fact zero.181
Walton: Yes. And the problems that began to escalate in the 1980s or in the late 1970s
and increased in the 1980s, in some respects pale into insignificance with the
problems that we are now facing. As some of you may know, I chaired a House of
Lords Select Committee enquiry which reported two years ago on clinical research in
the NHS in the light of the government reforms. We had high hopes of the Culyer
mechanism,182 which was one of the things we recommended; we hoped that that
particular R&D programme would result in considerable improvement in research in
the NHS. But in the meantime clinical academic medicine is in a parlous state. We
identified 57 vacant clinical chairs in the UK for lack of suitable applicants. We
identified the fact that clinical academic careers, as Bill Hoffenberg commented, are
now even less attractive than they were because of the unremitting pressure from
managers in the NHS upon clinical academics who, they believe, many of them, to be
just as much responsible for the work of the NHS as the NHS consultants. They are
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applying increasing pressure upon them to see more and more patients and to reduce
waiting lists to the detriment of teaching and research. And the terms and conditions
of service of the clinical academics are still in many respects less attractive than those
in the NHS. One could go on, but the Richards Report,183 which arose out of our
enquiry into research in the NHS, has made a number of important recommendations
relating to the future of clinical academic medicine. The Vice-Chancellors are still
sitting on that report, very reasonably, because to implement its recommendations will
cost money which the universities at the present time don’t have. I don’t want to be
too gloomy. I believe that the future of academic medicine in the UK is still bright,
but it is going to need enormous energy and dedication from people in the field to try
to draw in the funding that is going to be so crucial to the future of British medical
research. I have been fascinated to hear all that has been said today and I really believe,
Tilli, that we shall have a very readable document at the end of the day. Thank you
for inviting me to chair the meeting. 
183 An extended account of Lord Walton’s statement is given in Hansard, 8 December 1999, col. 1329.
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